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All these asthma characteristics appear to be interrelated [5] and if the disease is 
persistently treated inadequately, this may result in the loss of asthma control and 
accelerated decline of lung function. Since none of these asthma features or under-
lying inflammatory mechanisms are present in healthy, non-asthmatic individuals, it 
is necessary to conduct a trial with a novel therapy on patients as soon as possible in 
early clinical proof of concept (poc) studies.
When a relevant allergen is inhaled by sensitized patients with allergic asthma, it 
can induce various airway responses [6]. An immediate or early asthmatic response 
(ear) is characterized by a fall in the forced expiratory volume in one second (fev1) 
of ≥ 15 % from baseline within 10 to 30 minutes following inhalation of the allergen. 
The ear is an IgE-triggered phenomenon, mainly caused by mast cell release in-
ducing acute bronchoconstriction, and usually resolves within one to three hours. 
In about 50 % of such patients an ear is followed by a late asthmatic response (lar), 
characterized by prolonged airway narrowing, often defined as a fall in fev1 of ≥ 15 
% occurring between three and eight hours post-allergen exposure in which th2 
lymphocytes, activated eosinophils, their pro-inflammatory and toxic products play 
a key role, Figure 2. These sequelae may last for several days or weeks and result in the 
development of the allergen-induced ahr.
pathophysiology of asthma w Two main types of T helper lymphocytes 
have been characterized: th1 and th2. th1 cells produce (amongst others) inter-
leukin (il)-2 and ifn-γ, which in general are critical in cellular defense mechanisms 
when responding to infection. th2-cells generate a family of interleukins that can 
mediate allergic inflammation, Figure 3 [7]. The th2-cells produces il-4 and il-13 
(causing B cell immunoglobulin (Ig) E production), il-5 (causing eosinophilic in-
flammation) and il-9 (promoting mast cells growth). Traditionally, it is thought 
that in atopic asthmatic patients, allergens tend to induce an unbalanced production 
of the th2 type cytokines, but little of the th1 cytokines.
new insights w For many years asthma was considered a straight forward 
disease driven by aberrant th2 immunity. This hypothesis made it possible to un-
derstand classic allergic asthma, its association between atopy, eosinophilic lung 
inflammation, and the effect of corticosteroid treatments to reduce the th2 type 
inflammation. However, it cannot explain why residual disease remains after opti-
mized anti-inflammatory treatment. Also, numerous new targets for the treatment 
of asthma like key anti-interleukins 4 and 13 [8] and anti-interleukin 5 [9], have been 
based on this th2 inflammation model but this approach has shown no or marginal 
introduction 
Imagine working as a researcher at an independent research institute, a contract re-
search organization with close connections to academia (www.chdr.nl). Recently, 
a new pharmaceutical company contacted your organization after they acquired a 
new compound with a mode of action possibly suitable for the treatment of asth-
ma. Preclinical studies show promising results and expectations are high. Since the 
pharmaceutical company is small, it seeks external advice on how to perform a first 
in human study specifically, and on a drug development plan in general. As a clini-
cal pharmacology researcher you are asked to advise the company how to proceed in 
demonstrating safety and unlock the blockbuster potential of the compound, under 
the constraint of limited time and budget.
This introduction describes several aspects that should be considered in the de-
velopment of potential anti-asthmatic drugs as an example for drugs that may be 
developed for respiratory diseases. The same strategy could also be considered for 
other respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary dis-
ease, but these disease entities and possible therapeutics are not discussed in this vi-
gnette case. The clinical features and pathophysiology of asthma, the added value of 
animal models, a general overview of asthma drug research and finally an overview 
of commonly uses biomarkers for asthma are described.
asthma
epidemiology w Asthma is estimated to affect 300 million individuals world-
wide [1;2]. The prevalence of asthma and associated allergic syndromes is increasing 
worldwide and the currently available drugs are not equally effective in all patients 
[3]. Hence there is still a demand for novel, targeted anti-asthma therapy.
clinical characteristics w Asthma is a chronic inflammatory disorder 
of the airways, often associated with atopy (allergy). Clinically, variability of symp-
toms and airway obstruction is the most striking phenomenon. The pathogenesis 
is still not fully elucidated, but chronic airway inflammation and airway hyper-re-
sponsiveness (ahr), an excessive response to triggers that have little effect in normal 
individuals, represent the key characteristics in the pathophysiology of asthma [4]. 
Along with these more or less dynamic features, structural changes of the airways 
(the so-called airway remodeling) occur early on in the disease, Figure 1. 
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is similar to the disease in humans [15;16]. Moreover, many antigen challenge tests 
used in animals result in an acute inflammation phenotype and bypasses the etiol-
ogy of asthma which develops over time through multiple step processes [17]. Even 
if longer duration models are used in animals with repeated exposure to allergens for 
many weeks, important clinical endpoints of human asthma do not develop such as 
chronic inflammation of the airway wall and airway remodeling [18;19]. 
the drug development process for 
potential new pulmonary therapeutics
There are several possible classifications for the process of clinical drug develop-
ment. Classically, drug development is considered to be a linear consecutive process 
in which drugs passes through four clinical phases of development [20], Figure 4. 
After each phase a Go/No Go decision is made where the drug progresses into later 
development, or the drug development program is discontinued. Generally, phase I 
trials, usually in healthy volunteers, are used to determine safety and sometimes also 
aim to investigate the pharmacokinetic profile of the drug (absorption, distribution, 
metabolization and excretion); phase ii trials are used to get an initial understanding 
of efficacy and further explore safety in small numbers of patients; phase iii trials are 
large, pivotal trials to determine safety and efficacy in sufficiently large numbers of 
patients and are often used to request market approval; and phase iv trials are post-
approval trials and sometimes a requirement from the agencies for the evaluation of 
medicinal products.
The classification of drug development into proof of mechanism, proof of con-
cept and proof of principle studies are related to the concept of these four phases. 
The underlying principle for these studies is use of biomarkers as surrogate end-
points [21]. In early development establishing the drug’s effectiveness in the targeted 
disease population is not required, and instead surrogate endpoints are often used to 
guide decisions on further testing. 
Proof of Mechanism (PoM). These studies often refers to early drug development 
in the preclinical phase (animal models), but sometimes this term is also used for 
testing pharmacodynamic effect of the drug in healthy volunteers. The intention is 
to show that the drug is available at the targeted site of action and that its interac-
tion with the intended receptor results in a desired biological effect. It serves as an 
indication for the intended pharmacodynamic effect and is an important tool for 
effect in the clinic. In addition, the th2 inflammation model cannot explain some 
of the endophenotypes for asthma [10]. Asthma is nowadays recognized as a com-
plex heterogeneous syndrome consisting of many different subtypes (e.g. intrinsic, 
extrinsic, seasonal, exercise induced, virally induced, aspirin sensitive, allergic, non-
allergic, nocturnal and steroid resistant) each with different pathophysiology, ex-
pression of symptoms, response to treatment and prognosis. Lately, the role of the 
innate immune system with its Toll like receptors (tlr) and macrophages, originally 
thought of as a first defense against infections, has been more emphasized in relation 
to asthma [11;12].
toll like receptors and asthma w Before the immune system reacts, it 
must recognize the virus, bacterium or other infection. For the innate immune sys-
tem, these recognitions are carried out by soluble elements (e.g. complement, bind-
ing proteins) or by pattern recognition receptors (prrs) on macrophages, dendritic 
cells or polymorph nuclear leucocytes. The Toll like receptor is an example of a prr 
recognizing lipopolysaccharides (lps), a component of the outer membrane of 
Gram-negative bacteria. Provocation of the lung in asthma patients with lps induces 
a predominantly neutrophilic type of inflammation, acute and chronic forms of air-
way obstruction and even airway remodeling [13]. More specific, bone marrow de-
rived dendritic cells produce il-12 in response to high doses of lps, stimulating the 
th1 response, Figure 3. This suggests that the role of other pathways, like the th1 
pathway, may play a more important role in the pathophysiology than originally 
acknowledged.
added value of animal models
The first β2 agonist for the treatment of asthma was introduced to the market in 
1969 and corticosteroids were introduced since 1974. Since then, few new drugs have 
made it to the clinic. Multiple drugs performed well in preclinical animal models 
of asthma but did not live up to their promise in humans. Leukotriene antagonists 
(e.g. montelukast) and antibodies directed to immunoglobulin E (e.g. omalizum-
ab) are an exception, even though both have restricted clinical indications. 
There are several reasons for the limited utility of translating animal models to 
humans. It is suggested that asthma is a human disease only [14]. Several species and 
study designs have been used to try and mimic asthma. However, no animals, in-
cluding those frequently used to study asthma, exhibit an asthma like syndrome that 
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applicable biomarkers in asthma drug 
development
A biological marker (biomarker) is a physical sign or laboratory measurement that 
can serve as an indicator of normal biological processes, pathophysiological pro-
cesses or a pharmacological response to a therapeutic intervention. In asthma there 
are several validated pathophysiological and immunological biomarkers, and many 
others are being validated. In principle, all biological compounds of the asthma in-
flammatory cascade could serve as biomarkers. Ideally, a biomarker should have the 
following characteristics [24]: 
p  Clinical relevance: a clear relationship between the biomarker and the 
pathophysiological events leading to a well-defined clinical endpoint;
p  Reliability and repeatability: the measurements of the biomarker should  
be precise and reproducible;
p  Simplicity of sampling methodology, preferably via non- or semi-invasive 
sampling techniques, and measurement to promote widespread use; and,
p  Sensitivity and specificity for treatment effects.
p  Dose response relationship
Alongside safety data, it has become increasingly important to get as much informa-
tion on the drug’s potential efficacy as soon as possible in the early phases of drug 
development. Also, regulatory authorities have advocated the incorporation of 
validated biomarkers into early clinical studies to speed up drug development [25]. 
Therefore, in proof of pharmacology or proof of concept (poc) studies of asthma, 
biomarkers as read outs of pharmacological efficacy should be added. To obtain 
biomarkers containing tissue in asthma, bronchial biopsies are the ‘gold standard’. 
However, this invasive technology requires trained staff and expensive equipment, 
and therefore it is increasingly being replaced by more patient-friendly, non- or 
semi-invasive sampling techniques, which enables evaluation of biomarkers for in-
stance in blood, sputum or exhaled air. 
In the last decade, several non-invasive airway sampling techniques have been 
validated, yielding several biomarkers in induced sputum and exhaled air to better 
characterize respiratory disease entities. 
induced sputum w During the standard procedure [26] sputum is induced 
by serial inhalations of hypertonic saline solutions. This semi-invasive method has 
been validated over the past 15 years and requires the combination of a patient’s col-
laboration, investigator’s expertise, a well-equipped lab and a certified cytopatholo-
gist. Obtained sputum samples are processed and can be divided into a solid phase 
selection of appropriate dose for Proof of Concept studies. Proof of Concept (PoC) 
studies refers to clinical studies with a small group of patients. The aim of these stud-
ies is to show a useful clinical effect. Proof of Principle (PoP) studies are related to 
Phase iii studies and are generally used for registration purposes. Some 15 years ago 
it was realized by the fda and ema that classification of the drug development pro-
cess into four distinct phases provided an inadequate basis for classification of clini-
cal trials as a single trial could occur in several phases. Furthermore, they concluded 
that the typical sequence is not applicable for each drug. Therefore they came up 
with the classification of studies using study objectives, summarized in Table 1.
Although the fda and the ema have abolished the use of the four-phase termi-
nology for drug development, it is still widely applied amongst professional drug 
developers. The main reason for this is that this four-phase approach provides guid-
ance for the planning of clinical development of any new drug. However, as this is 
likely to be a valid approach for drugs with low uncertainty regarding the develop-
ment, it seems invalid for drugs with a high level of uncertainly. The uncertainty is 
based on the link between the molecular mechanism and its clinical effect, as well 
as its methodology to study it. It may be argued that a more useful model for drug 
development is the so called question based approach to drug development [22;23]. 
Question based drug developers make use of a logical progression of questions as 
shown in Figure 5. Does the drug get into the lungs? Does it reach the targeted re-
ceptors at its site of action? Will it affect the bronchodilation or its underlying in-
flammatory process in asthmatic patients? Does the drug have its pharmacological 
effect? For example, the mode of action of the new anti-asthmatic has to address the 
underlying endophenotype of asthma in the targeted patient population. What is 
the optimal dose with regards to meaningful clinical effects, and what is the thera-
peutic window? Other issues are whether the new anti-asthmatic drug has unwant-
ed side effects, and how variations in the targeted asthmatic population, for instance 
genetic variations or lifestyle differences, affect the effectiveness of the drug. In ad-
dition, an investigation whether the applicable biomarkers and linkage markers are 
validated for this purpose can be deemed of value. 
A schematic determination of objectives using this question based approach can 
be used to design a set of research questions to build the drug development plan. An 
integrated understanding of the fundamental principles of exposure at the site of 
action, target binding and expression of functional pharmacological activity deter-
mines the likelihood of the compound’s potential survival in early phase trials, and 
improves the chance of progression to subsequent development phases. Questions 
that remain unanswered make up the development risk.
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studies are the maximum early and late decrease in fev1, and the areas under the 
curve for the early response (ear; 0-2 h post challenge) and the late response (lar, 
3-8 hour post challenge). 
The most commonly used exacerbation model for the investigation of potential 
anti-inflammatory therapy is the allergen inhalation challenge. The reproducibil-
ity in this model is high [40]. In a cross over designed study, less than 10 subjects 
are needed to have 95% power for a 50% reduction of percent of eosinophils [41]. 
Applying the allergen challenge is revealed as an overall good predictor regarding a 
drug’s efficacy in asthma.
Methacholine has a direct effect on the airway smooth muscle via the musca-
rine-3 receptor. Its challenge test is the gold standard to quantify airway hyper re-
sponsiveness (ahr) by pc20. However, the test is less related to inflammation [42].
Another reproducible model inducing bronchoconstriction and airway hyper re-
sponsiveness (ahr) in healthy volunteers or asthmatic patients is the inhalation of 
lipopolysaccharide (lps) [43], which causes neutrophilic inflammation [44;45]. Like 
allergen challenges, lps challenges require close safety monitoring for airway and 
systemic effects. There are many more exacerbations models utilizing exposure to 
virus, ozone, adenosine 5 monophosphate, etc. These models are not described in 
detail as in this thesis only the allergen and methacholine challenges were applied.
In conclusion w For rapid and optimal evaluation of an investigative drug’s 
clinical efficacy, the use of both clinical measures and biomarkers is advocated. For 
asthma research with potential anti-inflammatory compounds, this could indicate 
the combination of an exacerbation model (e.g. allergen or lps challenge) with vali-
dated noninvasive airway sampling techniques (eno, sputum induction). In addi-
tion, drug development programs should proceed in a much more adaptive manner, 
using a question based approach.
The aim of this thesis is to discuss and highlight several aspects that should be 
considered in the development of potential new respiratory therapeutics. In early 
clinical research the goal is to bridge preclinical development of potential new drugs 
into successful next phase studies. Therefore, early phase clinical studies are designed 
generate understanding of clinical characteristics of the drug, to determine its safety 
and to predict effectiveness in the targeted population. Information about this is 
often obtained by effective integration of modern technologies and tools like bio-
markers into clinical development plans. 
and a fluid phase containing soluble (bio)markers. The cell pellet is cyto-spinned, 
stained, and cell differentials are then counted [27]. Ample evidence exists that spu-
tum eosinophil and neutrophil counts are reproducible biomarkers for allergic and 
non-allergic airway inflammation, allowing phenotyping and assessment of asthma 
severity [28;29]. Moreover, sputum eosinophil counts in patients with moderate to 
severe persistent asthma have been shown to be a superior guide of asthma con-
trol than traditional disease markers like symptom scores and lung function [30]. 
The fluid phase or the supernatant of the sputum can be analyzed by bioassays and 
many soluble markers can be quantified. This reflects on the disease severity and ac-
tivity e.g. pro-inflammatory mediators, cytokines, chemokines, neuropeptides and 
growth factors [31]. The technique of sputum processing is currently being opti-
mized to allow detection of a larger array of potential biomarkers in the supernatant. 
Novel methods including ultracentrifugation, sputum-dialysis and protease inhibi-
tion are being introduced and tested in combination with sensitive detection tech-
niques, such as Luminex assays, proteomics and metabolomics.
Exhaled Nitric Oxide w Exhaled nitric oxide (eno) is a sensitive marker of 
acute airway inflammation and its measurement is increasingly applied to diagnose 
and monitor asthma [32]. Over the past decades various methods have been report-
ed to measure eno. The currently recommended eno sampling method is performed 
by validated chemoluminescence analyzers during a single-breath exhalation 
against a fixed resistance, allowing reproducible (online) measurements [33]. This is 
a simple and patient-friendly procedure allowing serial measurements even in chil-
dren. More recently, another device has been introduced for online eno measure-
ments: the handheld electromechanic analyzer Niox Mino® whose measurements 
are reproducible and in agreement with the chemoluminescence analyzers [34]. In 
patients with allergic asthma uncontrolled by inhaled corticosteroids (ics), eno has 
been found to correlate with sputum eosinophils, and hence may qualify as a bio-
marker of asthma control [35]. Indeed, ics and other anti-eosinophil therapies, in-
cluding leukotriene modifiers and anti-IgE, dose-dependently reduced eno [36;37]. 
In the same way, several tapering studies have demonstrated that loss of asthma con-
trol is associated with an increase in eno [38]. Hence, eno is increasingly applied as a 
biomarker in the diagnosis, treatment monitoring and clinical trials of asthma. 
 
exacerbation models w Exacerbation models are useful tools in clinical 
poc studies for asthma [39]. The crux of these models consists of a validated stimulus 
that is capable of inducing a reproducible, more or less specific, inflammatory re-
sponse within the asthmatic airways (Figure 2). The endpoint measurements in such 
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section 2
clinical studies with a new anti-asthmatic drug
chapter 6 Chapter 6 describes the development process of a potential new 
anti-asthmatic drug, the combined pde 3/4 inhibitor rpl554. The purpose of this 
first in man study was to identify a potentially effective dose and to assess in an 
early stage whether rpl554 possesses bronchodilative, bronchoprotective and anti-
inflammatory properties in patients with allergic asthma and rhinitis. To this pur-
pose a step by step adaptive design was used in which a safe dose of rpl554 was 
selected in healthy volunteers, a potentially effective dose was selected in patients 
with allergic asthma and finally, rpl554 effects were evaluated in more depth in both 
patients with allergic asthma and patients with allergic rhinitis. The use and evalu-
ation of several technologies and biomarkers while using an adaptive study design 
are described in chapter 6.
chapter 7 The next step in the development of rpl554 was to assess its effec-
tiveness after repeated administrations. In this chapter the results on lung function 
are presented after repeated daily dosing of rpl554 for several consecutive days in 
order to evaluate the sustainability of effect on fev1. 
chapter 8 Chapter 8 covers the discussion and conclusion section. It includes 
a critical evaluation of the biomarker selection and drug development program for 
rpl554. 
This thesis consists of two main parts; it covers biomarker development and evaluation 
in section 1 and the early clinical development of a new anti-asthmatic drug in section 2.
 
section 1
biomarker development and evaluation
chapter 2 In this chapter the development of a novel method to evaluate well-
known and unknown biomarkers is described. By applying an allergen challenge in 
patients with clinical stable asthma, a large set of inflammatory th2 derived markers 
obtained from induced sputum were evaluated. The ability to quantify changes in 
these cytokines in sputum after an allergen challenge could be useful to assess effects 
of anti-asthma therapeutics.
chapter 3 Microarray assessment of gene expression in induced sputum ob-
tained after allergen challenge was applied in the same study as described in chapter 
2. Using this method, it was evaluated whether an rna signature could be identi-
fied from induced sputum following an inhaled allergen challenge, whether a gene 
signature could be modulated by limited doses of inhaled fluticasone, and whether 
these genes would correlate with the clinical endpoints measured in this study.
chapter 4 Fractional exhaled nitric oxide feno is a sensitive marker of acute 
airway inflammation. However, it has been shown that feno levels may be reduced 
after sputum induction by hypertonic saline in asthmatics and healthy controls. It is 
unknown if this phenomenon also occurs in asymptomatic chronic smokers, a popu-
lation at risk to develop copd. This was investigated and described in chapter 4.
chapter 5 The reproducibility of the measurements of many soluble mediators 
in the supernatant of hypertonic saline-induced sputum and serum is still unknown. 
This hampers their use in clinical trials as possible read-out for treatment effect. 
Therefore we evaluated the reproducibility of a specific panel of soluble biomarkers 
in sputum and serum on healthy non-smokers and asymptomatic chronic smokers 
and this is described in chapter 5. 
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Define/describe pk and pd









Explore use for the targeted indication
Estimate dosage for subsequent studies
Provide basis for confirmatory study design,  
endpoints, methodologies
Earliest trials of relatively short duration in  
well- defined narrow patient populations, 
using surrogate or pharmacological 






Provide an adequate basis for assessing the  
benefit/risk relationship to support licensing
Establish dose-response relationship
Adequate, and well controlled studies to 
establish efficacy 
Randomized parallel dose response studies
Clinical safety studies
Studies of mortality/ morbidity outcomes
Large simple trials
Comparative studies
Therapeutic Use Refine understanding of benefit/
risk relationship in general or special 
populations and/or environments
Identify less common adverse reactions
Refine dosing recommendation
Comparative effectiveness studies
Studies of mortality/morbidity outcomes




Figure 1 Schematic relationship among asthma characteristics
asthma characteristics
Symptoms
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Figure 2 Early and late airway response after inhalation of grass pollen (this thesis)
Figure 3 Pathogenesis of asthma
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Figure 4 The classical drug development plan
Figure 5 Schematic determination of objectives using the question based approach to drug development 
(Figure is reproduced and adapted with permission from reference [22])
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introduction 
Inhaled allergen challenge is a highly reproducible, integral disease model enabling 
the investigation of several features of asthma [1]. Allergen challenge can be applied 
to study the pathophysiology and, if complemented with (non-) invasive airway 
samplings, the immune-biology to allergic stimuli within the airways. In drug de-
velopment, allergen challenge is an established tool predicting clinical efficacy of 
novel anti-allergic and anti-asthma treatments [2]. 
Non-invasive airway sampling by hypertonic saline-induced sputum [3] has been 
shown to yield reproducible increases in inflammatory cells and biomarkers follow-
ing allergen-induced late asthmatic response (lar) [4] with subsequent response to 
novel and existing anti-inflammatory therapies [2;4-6]. While animal studies pro-
vided evidence of th2 cytokine response following allergen challenge, supported by 
some human studies applying bronchoscopy [7;8], no consistent data exist on repro-
ducible quantification of th2 cytokines and chemokines in sputum. Accountable 
factors include degradation by standard sputum processing with dithiothreitol 
(dtt), which destroys the disulphide bounds of these inflammatory markers [9], 
overall low baseline concentrations and relatively insensitive detection techniques. 
Some of these hurdles could be overcome by physical homogenization of sputum 
samples by ultracentrifugation causing cellular disruption with subsequent release 
of intracellular products in combination with sensitive detection techniques [10;11]. 
Combining sputum ultracentrifugation with novel, sensitive quantification 
techniques using Mesoscale multi-array microplates [12] in the allergen challenge 
model, we aimed to study: 1) the feasibility of the quantification of th2 cytokines 
and chemokines in sputum at 7 and 24 h post-challenge, 2) their reproducibility and 
3) their reversibility after a short course of inhaled fluticasone (fp). Furthermore, 
to allow comparison with other established markers of allergen-induced airway 
inflammation, we also measured the allergen-induced airway responses (i.e., the 
early (ear) and late (lar) asthmatic response), exhaled nitric oxide (eno), sputum 
cell differentials and the provocative concentration of methacholine causing a fall 
in forced expiratory volume in 1 second (fev1) of 20% (pc20fev1Methacholine) at 
baseline and 24 h post allergen, during all study periods. 
methods 
Study population and design w Thirteen non-smoking subjects with 
clinically stable, mild to moderate allergic asthma [13] using prn short-acting 
abstract
background  Allergen-induced late airway response offers important phar-
macodynamic targets, including T helper 2 (th2) biomarkers. However, detection of 
inflammatory markers has been limited in dithiothreitol-processed sputum.
objectives  To test whether allergen-induced th2 inflammatory markers 
can be reproducibly quantified by sensitive detection techniques in ultracentrifuged 
sputum and the effect of fluticasone on these endpoints.
methods Thirteen allergic asthmatics with dual allergen-induced airway re-
sponses documented during a single-blind placebo run-in period, participated in 
a double-blind, 2-period cross-over study. Each period consisted of 3 consecutive 
days, separated by ≥3 weeks. Following randomization, subjects inhaled fluticasone 
(500 μg bid, 5 doses total) or placebo. On day 2 in each study period, allergen chal-
lenge was performed and airway response measured by fev1 until 7 h post-chal-
lenge. Sputum was induced 24 h pre- and 7 & 24 h post-allergen. Sputum samples 
were split into 2 portions: th2 biomarkers were quantified by Mesoscale multi-
plex platform following ultracentrifugation and cell differentials were counted on 
Giemsa-May-Grünwald-stained cytospins. Allergen-induced changes in inflam-
matory endpoints were compared between fluticasone and placebo using a mixed 
model ancova.
results Inhaled allergen-induced dual airway responses in all subjects during 
both placebo periods with reproducible late asthmatic response (lar) and increases 
in sputum inflammatory biomarkers (il-2, il-4, il-13 and eotaxin-1) and eosino-
phil counts. Fluticasone effectively blunted both the lar and the inflammatory 
biomarkers.
conclusions Combining novel, sensitive quantification methods with ultra-
centrifugation allows reproducible quantification of sputum biomarkers following 
allergen challenge, reversed by fluticasone. This approach allows non-invasive iden-
tification of pharmacodynamic targets for anti-asthma therapies.This study is regis-
tered under eudract number 2007-003671-40.
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period served as a dose (range) finding procedure, while during study periods 1 
& 2 each subject inhaled the same 2 or 3 cumulative doses of the allergen extract 
that had caused a fall in fev1 of at least 15% from baseline during the run-in pe-
riod. Following diluent, incremental doubling concentrations (7.81 to 2,000 bu/
mL) of hdm extract (Dermatophagoides pteronyssinus; sq 503, alk-bpt, alk-
Abelló, Almere, The Netherlands) in phosphate-buffered saline (pbs) were aerosol-
ized by a calibrated jet-nebulizer (DeVilbiss 646, output 0.13 mL/min, Somerset, 
Pennsylvania, usa) and inhaled at approximately 12 min intervals, until the ear was 
reached (defined as a decrease in fev1 of > 15% from post-diluent baseline with-
in 1 h post-allergen). Airway response to inhaled allergen was measured by fev1 
in duplicate on a calibrated spirometer (Vmax Spectra; Sensor Medics, Bilthoven, 
The Netherlands) according to standard procedures [17], at 10, 20, 30, 45, 60, 90 and 
120 minutes and then hourly until 7 h after the last allergen inhalation. The highest, 
technically valid measurement was expressed as percentage decrease from post-dilu-
ent baseline fev1 and included into the analysis.
Methacholine challenge w The methacholine challenge was performed 
using standard methodologies [15]. Serial doubling concentrations of methacholine 
bromide (mbr, Janssen Pharmaceutical, Beerse, Belgium) diluted in normal saline 
(NaCl 0.9%) to serial doubling dilutions of 0.15-80 μmol/mL, were aerosolized 
by a calibrated jet-nebulizer (DeVilbiss 646 ) at 5 minutes intervals and inhaled by 
the subjects by tidal breathing for 2 minutes through the mouthpiece with the nose 
clipped. Airway response was measured by fev1 at 30 and 90 seconds (and poten-
tially at 180 seconds as well) following each concentration, and the lowest, technical-
ly satisfactory fev1 was implicated into analysis. Nebulization was continued until a 
> 20% fall in fev1 from post-diluent baseline.
After both bronchoprovocation tests, subjects received salbutamol through an 
aerochamber, until the fev1 returned within 10% of the baseline value.
Exhaled nitric oxide (eno) w All eno measurements were per-
formed according to current guidelines [14] using a chemiluminescence ana-
lyzer (Ecomedics cld88sp; Ecomedics, Duernten, Switzerland), which had to be 
replaced by a niox mino®(Aerocrine ab, Solna, Sweden) during the study. niox 
mino was used for subjects 8, 9, 10, 11, 12 and 13 during both study periods. In a previ-
ous study at our institute, both analyzers yielded similar values [18].
sputum induction, processing and analysis w Sputum induc-
tion was performed as previously described [16;19] using a DeVilbiss Ultraneb 2000 
beta2-agonists only and with dual airway responses to inhaled house dust mite 
(hdm), documented during the single-blind placebo run-in screening period, par-
ticipated in a double-blind, 2-way cross-over study. Each period consisted of 3 con-
secutive days, with ≥3 weeks washout between periods [Figure 1]. The screening, al-
lowing to test the reproducibility of the variables, was identical to the subsequent 
treatment periods during which subjects randomly received inhaled fp (mdi, 500 
μg bid, total of 5 doses) or matching placebo. On day 1, baseline measurements in-
cluding eno, spirometry, followed by methacholine challenge (pc20fev1Metha-
choline) and subsequent sputum induction (3 x 5 min NaCl 4.5%) were performed 
prior to study medication. On day 2, 1 h post-study medication, subjects underwent 
a titrated allergen challenge [1]. The subsequent airway response was repeatedly 
measured by fev1 until 7 h post-allergen. eno was measured pre- and 3 h and 7 h 
post-allergen; the latter followed by sputum induction. At 24 h post-allergen (day 
3), test-procedures were repeated as on day 1 [Figure 2]. All test-procedures were 
conducted according to standardized, validated methods and at the same time of the 
day (within 2 hours) [1;14-16]. 
A dual airway response to inhaled hdm extract consisted of an early (ear) and a 
late asthmatic response (lar) defined as a fall in fev1 > 15% from baseline occurring 
between 0-3 h and 3-7 h post-allergen, respectively. 
The study was approved by the Ethics Committee of Leiden University Medical 
Center, Leiden, The Netherlands, and all participants gave a signed informed con-
sent (eudract number 2007-003671-40). All procedures were performed in accor-
dance with the Helsinki Declaration of 1975, revised in 2008.
Study medication and dosing rationale w Fluticasone 250 μg/puff 
(Allen & Hanburys, Glaxo Wellcome Ltd, Middlesex, uk) and matching placebo 
(Armstrong Pharmaceuticals Inc., Canton, ma, usa, packaged at Merck Frosst, 
Kirkland, Canada) were supplied in identical metered dose inhalers (mdis) and in-
haled per single puff through an Aerochamber (Volumatic, GlaxoSmithKline, Zeist, 
The Netherlands). The rationale for the dose regimen was based on a previous study 
showing substantial reductions in allergen-induced lar, non-specific airway hyper-
responsiveness (ahr) and sputum eosinophils already following one single dose of 
inhaled fp 250 μg [6]. Thus, to ensure optimal reversal of the allergen-induced in-
flammatory markers versus placebo, a total of 5 fp doses (500 μg per dose) were ad-
ministered throughout the active treatment period. 
Allergen challenge w The allergen challenge was performed using the 2 
minutes tidal breathing method that has been previously validated [1]. The run-in 
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cell counts were analyzed using the change from baseline for the square root trans-
formed values. Geometric mean baseline sputum biomarker concentrations were 
calculated; half of the lower limit of quantification (lloq) was used in case of nega-
tive outcomes. Changes in sputum biomarker concentrations were analyzed after 
log-transformation and expressed as fold change from baseline. 
The airway response to inhaled allergen was expressed as percentage decrease 
in fev1 from post-diluent baseline and plotted as time–response curves during all 
treatment periods. The difference in fev1 during both the ear and the lar was ana-
lyzed using the time weighted average of percentage change and the maximum per-
centage charge from baseline. Subject 1 had an initial fev1 decrease of slightly under 
15% at 7 h post-allergen, but met the inclusion criterion at 8 h post-allergen and was 
included in the study. Therefore, for this subject fev1, cytokines, chemokines and 
eno were consequently measured at 8 h during all periods. fev1 results at 8 h were 
not included into the analysis. 
pc20fev1 Methacholine was calculated by linear interpolation on a plot of log-
concentrations versus response using methacholine concentrations below and above 
a 20% fall in fev1. The (allergen-induced and fp-reverted) changes in pc20fe-
v1Methacholine were expressed in doubling doses. eno was expressed as a fold 
change from baseline at 3, 7 and 24 h post-allergen. 
Reproducibility of the allergen-induced airway responses and sputum inflamma-
tory markers was assessed using data from the run-in and study placebo periods. The 
intra-class correlation coefficient (icc) was calculated, and a 2-sided paired t-test 
was performed.
Sample size w In the absence of information about variability in tnf- α and 
il-13 concentrations in sputum, eosinophil count was used as an approximate vari-
able for sample size estimation [21]. Power calculation showed that the study would 
have > 90% power (α = 0.05, one tailed) to detect a five-fold increase from baseline at 
7 h post-allergen challenge with 12 completing subjects. 
results 
Subjects w Fifteen subjects were considered eligible after completion of the 
run-in period. Before randomization, two subjects were withdrawn: one had a posi-
tive cotinine test, while the other repeatedly presented with a clinically relevant 
bronchoconstriction (baseline fev1 <70% predicted). Thus, 13 subjects were random-
ized and all completed the study [Table 1].
ultrasonic nebulizer (Tefa Portanje, Woerden, The Netherlands) connected to a 100-
cm long plastic tube, with an internal diameter of approximately 22 mm, connected 
to a two-way valve (No.2700; Hans-Rudolf, Kansas City, mo, usa) with a mouth-
piece. Hypertonic saline (NaCl 4.5%) was nebulised and inhaled through the 
mouth, with the nose clipped, during three periods of 5 minutes. At approximately 
7 minutes following each induction, spirometry was performed as a safety measure.
Collected sputum samples were divided into two portions of equal weight. The 
cell pellet of the first portion was processed as a full sample according to guidelines 
[16;20], using 0.1% dtt (Sputolysin, Calbiochem, La Jolla, ca, usa). Cell viability 
and total cell count were assessed using Trypan Blue; sputum samples containing 
> 80 % squamous cells were excluded from analysis. Differential cell counts were 
performed by a qualified cytologist on May-Grünwald-Giemsa stained, coded cyto-
spins and expressed as percentage of 500 nucleated, non-squamous cells.
The second sputum portion was used to quantify soluble inflammatory markers. 
At Merck Research Laboratories, defrosted samples were pretreated with a prote-
ase-inhibitor cocktail (50 μL per 200 mg sputum), prepared by dissolving one pro-
tease cocktail tablet (Complete Protease Inhibitor Cocktail tablets, Roche Applied 
Science #11 697 498 001) into 50 mL of pbs (Invitrogen cat. no. 14040). Prepared 
sputum samples were subsequently ultracentrifuged in an ultracentrifuge (Beckman 
Coulter Inc. Optima Max Ultracentrifuge 130,000 rpm; Fullerton, ca, usa) at 
35,000 rpm (53,500 x g) for 90 minutes at 4°C. Subsequently, sputum supernatant 
was collected and analyzed.
Cytokine and chemokine measurements w Quantification of 
soluble biomarkers in sputum samples was performed using an msd (Mesoscale 
Discovery, Gaithersburg md, usa) Singleplex kit (il-13), an msd duplex kit (eotax-
in-3 and tarc) and two msd multiplex assays (il-1β, il-2, il-4, il-5, il-8, il-10, il-
12p70, ifn-γ, tnf-α, eotaxin, ip-10, mcp-1, mcp-4, and mip-1β). All concentrations 
were expressed as pg/mL.
Statistical analysis w Data of all randomized subjects were included 
into the analysis. The effect of fp versus placebo on the th2 cytokines, chemokines 
and other inflammatory markers at 7 h and 24 h post-allergen was assessed using 
a mixed effects analysis of variance (anova) model. The model included fixed fac-
tors for sequence, treatment, and period, and a random effect for subjects within 
sequence. Between treatment differences were estimated by the difference in least-
square means from the model with 90% ci (one-sided alpha = 5%). Sputum cell 
differentials were analyzed using the actual change from baseline, while absolute 
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At 7 h post-allergen many soluble markers were reproducible, especially il-2, il-4, 
il-13, and eotaxin-1 showed an interclass correlation coefficient (icc) values greater 
than 50%, with more variation between subjects than within subjects. At 24 h, none 
of the inflammatory markers had icc values greater than 50%. Cytokine baseline 
values on day 1 for each treatment period are provided in Table 5.
change in eno w Compared to baseline, eno levels did not significantly in-
crease at 3 and 7 h post-allergen and were not different between placebo and fp. At 
24 h post allergen, however, a significant increase in eno was measured (1.63 fold and 
90%ci: 1.2; 2.3) which was blunted by fp (0.83 fold, 90%ci: 0.6; 1.2), resulting in a 
significant difference between placebo and fp of 49% (p=0.012, 90%ci: 19;68).
discussion 
In this study, we have been able to reproducibly quantify several th2 inflammatory 
cytokines and chemokines in sputum from allergic asthmatic subjects following in-
haled allergen. The increase in these soluble sputum biomarkers was consistent with 
other established allergen-induced inflammatory responses and most robust at 7 h 
post-allergen, coinciding with the maximal fall in fev1 during the lar. Fluticasone 
significantly blocked both the allergen-induced airway response and the major-
ity of the inflammatory markers in sputum. Although other researchers previously 
showed a similar inflammatory response in bronchoalveolar lavage [7] and in spu-
tum [22-24], none of them has investigated such wide range of allergen-induced 
th2-cytokines and chemokines or their reversibility to corticosteroid treatment. 
The use of sulfhydryl-reducing reagents, such as dtt, has complicated the de-
tection of inflammatory cytokines and chemokines and alternative processing tech-
niques enabling the measurement of e.g. eotaxin have previously been published 
[9]. In our study sputum samples were ultracentrifuged [10] instead of being pro-
cessed with dtt to avoid potentially degrading effects on several th2 cytokines 
and chemokines [9]. Following this ‘boosting’ step, substantial allergen-induced 
increases in several cytokines and chemokines could be reproducibly quantified 
using sensitive detection techniques (Mesoscale multi-array microplates). However, 
reproducibility was lost for most soluble markers and sputum eosinophils at 24 h 
post-allergen. 
 In parallel with reproducible increases in the th2-derived inflammatory markers, 
we were able to demonstrate reproducible changes in the established allergen-induced 
Safety w No serious adverse events occurred. Headache and fatigue were the 
most frequently reported adverse events. All events were mild in intensity and clas-
sified as unrelated to the study medication or procedures. 
Allergen-induced airway responses w Inhaled hdm induced both an 
ear and an lar in all subjects during both placebo periods. Compared to placebo, 
fp significantly reduced the ear and completely blunted the lar [Figure 3]. The 
reproducibility of the allergen-induced lar during both placebo periods was good, 
both in terms of the maximum %fall in fev1 from baseline and as time weighted 
average (3-7 h post-allergen), with an icc of 79.7% and 69%, respectively [Table 2].
allergen-induced non-specific airway hyperresponsiveness 
(ahr) w During both placebo periods, allergen challenge increased non-specif-
ic ahr, by decreasing pc20fev1Methacholine at 24 h post allergen by on average 
1.18 (90%ci: 1.73; 0.64) doubling doses. In contrast, fp increased 24 h post-allergen 
pc20fev1Methacholine by on mean 1.60 doubling doses (90%ci: 1.06; 2.15), result-
ing in a mean difference of 2.79 doubling doses (90%ci: 2.07; 3.51; p < 0.001) between 
placebo and fp [Figure 4].
Sputum inflammatory cells w A sputum sample was obtained from all 
subjects at all occasions. The average squamous cell contamination was 36% (range: 
2-71%). Sixteen of 117 samples were not analyzable. Inhaled allergen significantly in-
creased sputum eosinophils both at 7 and 24 h post-challenge during both placebo 
periods. This effect was significantly reduced by fp [Table 3]. The reproducibility for 
both sputum eosinophil count (icc: 76%) and percentage (icc: 88%) was high at 7 h 
post-allergen, but poor (icc 0 %) at 24 h.
sputum (th2) cytokines and chemokines w During placebo treat-
ment, inhaled allergen increased sputum inflammatory cytokines and chemokines 
both at 7 and 24 h post-allergen, yielding the most robust increase at 7 h, Table 4. 
Fluticasone significantly blunted the allergen-induced increases in sputum concen-
trations of il-5, il-13, tarc, eotaxin-3, mcp-1, eotaxin-1 and il-4 at 7 h post-aller-
gen challenge and of il-5, il-13, eotaxin-3, il-12p70 and mcp-1 at 24 h post-allergen 
challenge. None of the other sputum soluble markers were significantly affected by 
fp compared to placebo treatment. At 24 h post-allergen, there was no difference in 
any sputum inflammatory markers, with the exception of tarc between both pla-
cebo treatments.
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Table 1 Baseline characteristics of randomized subjects
Number of subjects 13
Age (years) 25.9 (21-43)
Gender 4M/9F
bmi, (kg/m2) 24.4 (16.6-39.8)
fev1 (L) 3.57 (2.92-4.50)
fev1 (% pred) 94.0 (74.5-112.3)
pc20fev1Methacholine (μmol/ml) 12.8 (0.8-81.5)
spt hdm Wheal (mm) 5.5 (2.5-10.5)
eno (ppb) 53.4 (11.2-160.8)
 Numbers are expressed in mean (range), bmi = Body Mass Index,  
 spt hdm = Skin Prick Test for House Dust Mite, ppb = parts per billion
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inflammatory outcome [4;25;26], including the late asthmatic airway response, non-
specific airway hyperresponsiveness and sputum eosinophils, underscoring the valid-
ity of our data. In agreement with previous evidence, we also found increased eno 
levels at 24 h post-allergen [27] , while no significant eno increases could be observed 
at our cut off point during the lar, i.e., at 7 h post-allergen. Although previous stud-
ies showed increased eno levels at 9 and 10 h post-allergen, respectively [27] [28], the 
present findings can be explained by the use of two different measuring devices (for 
logistic reasons) and the time-lag required for the synthesis of inducible no synthase 
(i-nos), responsible for the synthesis of no [29].
Although in the present study no direct comparison was made with soluble 
markers from the dtt-processed sputum portion, the current approach yielded re-
producible data. In addition, the observation that fp can reverse the allergen-in-
duced increase in these inflammatory markers in parallel with its inhibitory effects 
on the other inflammatory events including the airway responses and cellular mark-
ers, suggests that this approach is sensitive enough to offer evaluation of therapeutic 
interventions in asthmatic subjects. 
In conclusion, combining novel, sensitive quantification methods with ultracen-
trifugation allows reproducible quantification of sputum biomarkers following an 
allergen-induced lar, which can be reversible by fluticasone. This approach allows 
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days of run in
randomization
> 21 days wash out
interval
> 21 days wash out
interval




Prestudy Run in Period Period 1 Period 2 Poststudy
placebo placebo
active drug active drug
Figure 1 Overview of the single-blind placebo run-in period and double blind cross-over  
study periods 1 and 2
Figure 2 Overview of study assessments. is = induced sputum, eno = exhaled nitric oxide. Time zero is time 
of first study medication dosing. The single-blind placebo run-in screening period and the subsequent study 
periods 1 & 2 were identical
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Figure 3 Time-response curves (mean ± sem) to inhaled allergen during run-in period, placebo treatment 
and fluticasone treatment, respectively
Figure 4 Changes in airway hyperresponsiveness 24 h pre- versus 24 h post-allergen during run-in period, 
placebo treatment and fluticasone treatment, respectively
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introduction
Inhaled allergen challenge can be applied to study the pathophysiology and the im-
mune-biology to allergic stimuli within the airways. Allergen challenge is highly 
reproducible and serves as an integral disease model enabling the investigation of 
several features of asthma [1]. In drug development, allergen challenge is an estab-
lished tool predicting clinical efficacy of novel anti-allergic and anti-asthma treat-
ments [2]. Hypertonic saline-induced sputum [3] has been shown to yield reproduc-
ible increases in inflammatory cells and biomarkers following allergen-induced late 
asthmatic response (lar) [4] with subsequent response to novel and existing anti-
inflammatory therapies [2;4-7].
Microarray technology allows to profile gene expression of the entire genome 
and has been widely applied in several asthma studies [8;9]. A large majority of these 
gene profiling studies involved tissue obtained from asthmatics like airway epitheli-
um [10;11], bronchial biopsies [12] or nasal mucosal cells [13]. Although gene expres-
sion has also been studied in fluids from asthmatics like blood [14], broncho-alveolar 
lavage [15], and induced sputum [16], little is published on extensive gene expression 
profiling on induced sputum cells following allergen challenge.
In this study Affymetrix 2.0 microarray technology was used to measure the gene 
expression levels of > 50.000 transcripts in induced sputum obtained from 13 allergic 
asthmatics before and after allergen challenge. In a refined set of 47 genes signatures 
we aimed to study: 1) the feasibility and reproducibility of quantification of gene 
expression in induced sputum at 7 and 24 hour post-challenge 2) their reversibility 
after a short course of inhaled fluticasone (fp) treatment, and 3) the correlation with 
lung function and eosinophil measurements.
methods
Study population and design w Thirteen non-smoking subjects with 
clinically stable, mild to moderate allergic asthma [17] using prn short-acting beta2-
agonists only and with dual airway responses to inhaled house dust mite (hdm), 
documented during the single-blind placebo run-in screening period, participated 
in a double-blind, 2-way cross-over study. Each period consisted of 3 consecutive 
days, with ≥ 3 weeks washout between periods, Figure 1. The screening was identi-
cal to the subsequent treatment periods during which subjects randomly received 
inhaled fp (mdi, 500 μg bid, total of 5 doses) or matching placebo. On day 1, baseline 
measurements including, spirometry and subsequent sputum induction (3 x 5 min 
abstract 
Rationale Inhaled allergen challenge is a validated exacerbation model of al-
lergic asthma offering useful pharmacodynamic assessment of pharmacotherapeutic 
effects in a limited number of subjects. 
Objectives To evaluate whether an rna signature can be identified from in-
duced sputum following an inhaled allergen challenge, whether a rna signature 
could be modulated by limited doses of inhaled fluticasone, and whether these gene 
expression profiles would correlate with the clinical endpoints measured in this 
study.
Methods Thirteen non-smoking, allergic subjects with mild to moderate asth-
ma participated in a randomized, placebo-controlled, 2-period cross-over study fol-
lowing a single-blind placebo run-in period. Each period consisted of 3 consecu-
tive days, separated by a wash-out period of at least three weeks. Subjects randomly 
received inhaled fluticasone ((fp) mdi; 500 mcg bid x 5 doses in total) or placebo 
pre- until 24 h post-allergen. On day 2, house dust mite (hdm) extract was inhaled 
and airway response was measured by fev1 at predefined time points until 7 h post-
allergen. Sputum was induced by NaCl 4.5%, processed and analysed at 24 h pre- 
and 7 & 24 h post-allergen. rna was isolated from eligible sputum cell pellets (<80% 
squamous of 500 cells), amplified according to nugen technology and profiled on 
Affymetrix arrays. Gene expression changes from baseline and fluticasone treatment 
effect were evaluated using a mixed effects ancova model at 7 and at 24 hours post 
allergen challenge. 
Results Inhaled allergen induced statistically significant gene expression 
changes in sputum, which were effectively blunted by fluticasone (adjusted p-value 
<0.025). 47 rna signatures were selected from these responses for correlation analy-
ses and further validation. This included th2 cytokines, chemokines, high affinity 
IgE receptor fcer1A, histamine receptor hrh4, and enzymes and receptors in the 
arachidonic pathway. Individual messengers from the 47 rna signature correlated 
significantly with lung function and sputum eosinophil counts.
Conclusion Our rna extraction and profiling protocols allowed reproducible 
assessments of inflammatory signatures in sputum including quantification of drug 
effects on this response in allergic asthmatics. This approach offers novel possibilities 
for development of pd biomarkers in asthma.
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Sputum induction, processing and analysis w Sputum induction 
was performed as previously described [20;22] using a DeVilbiss Ultraneb 2000 ul-
trasonic nebulizer (Tefa Portanje, Woerden, The Netherlands) connected to a 100-
cm long plastic tube, with an internal diameter of approximately 22 mm, connected 
to a two-way valve (No.2700; Hans-Rudolf, Kansas City, mo, usa) with a mouth-
piece. Hypertonic saline (NaCl 4.5%) was nebulised and inhaled through the 
mouth, with the nose clipped, during three periods of 5 minutes. At approximately 
7 minutes following each induction, spirometry was performed as a safety measure.
The cell pellet was processed as a full sample according to guidelines [20;23]. The 
processing took place within 2 h of collection. A dtt 0.1% solution (Dithiothreitol, 
Calbiochem, La Jolla, ca, usa) was mixed with a protease inhibitor pill (Complete 
Protease Inhibitor Cocktail tablets, Roche Applied Science #11 697 498 001; 1 pill per 
50 mL of solution). The volume of the entire sputum sample was determined and an 
equal amount of 0.1% dtt/protease inhibitor solution was added. Subsequently, the 
sample was mixed with a pipette and placed in a warm shaking bath for 15 minutes 
at 37 ˚C. The homogenized mixture was centrifuged at 390G (1500 rpm) during 10 
minutes. The supernatant was removed.
To determine cell viability and the total cell count, the cell pellet was re sus-
pended in 2 mL pbs and filtered; 50 μL of the suspension was mixed with 50 μL 
of Trypan Blue. Total cell counts were determined in a counting chamber (Bürker; 
Omnilab 402521) using a cell counter (Omnilab 7005333). Cytospin slides (50 μL/
cytospin; Shandon Cytospin 4, Thermon Electron Corporation, Runcorn, uk) 
were prepared by diluting the cell suspension with pbs in order to obtain approxi-
mately 0.5x 106 cells per mL, and subsequently centrifuged for 3 minutes at 254 G. 
Differential cell counts of eosinophils, neutrophils, lymphocytes, macrophages, epi-
thelial and squamous cells were performed on May-Grünwald-Giemsa-stained cy-
tospins by a certified cytopathologist. In each sputum sample, at least 500 nucleated 
cells, excluding squamous cells, were counted twice and the average percentage of 
each cell type was determined and expressed as percentage of nonsquamous cells. If 
> 80% of the cell count consisted of squamous cells, the quality of the sputum sample 
was judged unsatisfactory and was excluded from analysis.
The remaining suspension was centrifuged a second time. The resulting cell pellet 
was resuspended in 1 ml of trizol® (Invitrogen, Cat. # 15596-018, Life Technologies, 
Carlsbad, California, usa). rna was amplified using wt-Ovation® amplification 
technology (Nugen, San Carlos, California, usa). The amplified material was la-
beled and hybridized using a standard Affymetrix protocol. Gene expression stud-
ies were performed using the Rosetta/Merck Human rsta Custom Affymetrix 2.0 
microarray (Affymetrix, Santa Clara, California, usa) containing 51,562 probe sets 
NaCl 4.5%) were performed prior to study medication. On day 2, 1 h post-study 
medication, subjects underwent a titrated allergen challenge [1]. The subsequent air-
way response was repeatedly measured by fev1 until 7 h post-allergen. At 24 h post-
allergen (day 3), test-procedures were repeated as on day 1. All test-procedures were 
conducted according to standardized, validated methods and at the same time of the 
day (within 2 hours) during the different treatment periods [1;18-20].
A dual airway response to inhaled hdm extract consisted of an early (ear) and a 
late asthmatic response (lar) defined as a fall in fev1 > 15% from baseline occurring 
between 0-3 h and 3-7 h post-allergen, respectively.
This study was part of an allergen study measuring allergen induced th2-profile 
in sputum [7].
The study was approved by the Ethics Committee of Leiden University Medical 
Center, Leiden, The Netherlands, and all participants gave a signed informed con-
sent (eudract number 2007-003671-40).
Study medication w Fluticasone 250 μg/puff (Allen & Hanburys, Glaxo 
Wellcome Ltd, Middlesex, uk) and matching placebo (Armstrong Pharmaceuticals 
Inc., Canton, ma, usa, packaged at Merck Frosst, Kirkland, Canada) were supplied 
in identical metered dose inhalers (mdis) and inhaled per single puff through an 
Aerochamber (Volumatic, GlaxoSmithKline, Zeist, The Netherlands).
Allergen challenge w The allergen challenge was performed using the 
2 minutes tidal breathing method that has been previously validated [1]. The run-
in period served as a dose (range) finding procedure, while during study periods 1 
& 2 each subject inhaled the same 2 or 3 cumulative doses of the allergen extract 
that had caused a fall in fev1 of at least 15% from baseline during the run-in pe-
riod. Following diluent, incremental doubling concentrations (7.81 to 2,000 bu/
mL) of hdm extract (Dermatophagoides pteronyssinus; sq 503, alk-bpt, alk-
Abelló, Almere, The Netherlands) in phosphate-buffered saline (pbs) were aerosol-
ized by a calibrated jet-nebulizer (DeVilbiss 646, output 0.13 mL/min, Somerset, 
Pennsylvania, usa) and inhaled at approximately 12 min intervals, until the ear was 
reached (defined as a decrease in fev1 of > 15% from post-diluent baseline with-
in 1 h post-allergen). Airway response to inhaled allergen was measured by fev1 
in duplicate on a calibrated spirometer (Vmax Spectra; Sensor Medics, Bilthoven, 
The Netherlands) according to standard procedures [21], at 10, 20, 30, 45, 60, 90 and 
120 minutes and then hourly until 7 h after the last allergen inhalation. The highest, 
technically valid measurement was expressed as percentage decrease from post-dilu-
ent baseline fev1 and included into the analysis.
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results
Sputum specimens were collected from asthmatic subjects who provided a baseline 
specimen in period 1 and period 2 and which passed the quality control. The repro-
ducibility of the sputum induction and collection procedures for rna profiling after 
hybridization on microarrays, were evaluated by comparing individual gene expres-
sion intensities in combination with hierarchical clustering using Pearson correla-
tion coefficients [24], Figure 2. The results of this cluster analysis revealed that 14 out 
of 18 sputum specimens clustered appropriately in subject specific pairs, validating 
our sputum collection and isolation protocol.
The whole microarray contained 51,562 probe sets. At 7 hours post allergen chal-
lenge, and applying a false discovery rate of < 0.025, a total of 4.175 and 1.001 statis-
tical significant probe sets were identified for the allergen effect (ace) and the fp 
treatment effect (fte), respectively. Likewise, 1.143 and 1.018 statistical probe sets 
were identified at 24 hours post allergen for the allergen effect and the fp treatment 
effect, respectively. 714 probes sets were regulated by both the allergen challenge ef-
fect and fp treatment at 7 hours and 311 probe set at 24 hours post challenge, Table 
1. All the genes regulated by both the allergen challenge and fp at each time point 
were reversed from their allergen induced levels in presence of fluticasone, Figure 3. 
In other words, fluticasone effectively blunted the response to the allergen challenge 
at the gene expression level.
Quantification of the individual genes that contribute to the key cytokines of the 
th1, th2 and th17 pathways was performed by displaying the change from baseline 
in gene expression at 7 hours and 24 hours following allergen challenge in presence 
or absence of fp treatment (Figure 4). This analysis revealed the up-regulation by the 
allergen challenge and the down-regulation by fp treatment of the gene expression 
for several key th2 cytokines (Interleukin (il)-4, il-5 and il-13) and an absence 
of an effect on key th1 cytokines (Interferon (inf )-γ and Tumor Necrosis Factor 
(tnf )). Chemokine ligand 13 (ccl13)/Monocyte Chemoattractant Protein (mcp)-4 
[25], ccl17/ Thymus and Activation Regulated Chemokine (tarc) [26] and ccl26/
eotoxin-3 [27] are Inflammatory chemokines mediating th2 cell recruitment and 
known to be induced by il-4. Their gene expressions were up-regulated by the al-
lergen challenge and down-regulated by fp treatment following a similar pattern 
as the th2 cytokines (Figure 5). Likewise, the same pattern was observed for genes 
belonging to pathways controlling the release of inflammatory parameters like: hdc 
(histidine decarboxylase) known to catalyze the production of histamine [28]; hista-
mine receptor 4 hrh4 which is specific for eosinophils and basophils [29]; fcer1A, 
the alpha subunit of the high affinity IgE receptor which directly binds IgE and 
through crosslinking induces the release of preformed histamine and proteases as 
interrogating 50,159 human transcripts predominantly from refseq, GenBank, 
dbest and ensembl databases as described on the Gene Expression Omnibus 
website (https:// http://www.ncbi.nlm.nih.gov/geo/). The accuracy of sample pro-
cessing was monitored through quality metrics assessing rna yield, rna quality: 
18S/28S ribosomal rna ratio, rna Integrity Number (rin) score, and hybridization 
parameters: 3’/5’ ratios for gapdh mrna and scale factor. In addition, the amount of 
bacterial rna contamination was evaluated by calculating the area under the curve 
for the 16S and 23S (bacterial) versus the 18S and 28S (eukaryotic) ribosomal rna 
peaks using a bio analyzer electropherograms (Agilent, Santa Clara, California, 
usa). Specimens with more than 80% bacterial contamination were removed from 
the analysis. Data were normalized using the Robust Multichip Average (rma) al-
gorithm prior to statistical analysis. 
Statistical model for data analysis w A mixed effect ancova 
model was selected including terms for baseline gene expression, treatment, se-
quence and period as fixed effects and subject nested in sequence as a random effect. 
Gene expression change from the appropriate baseline was used as the dependent 
variable. The baselines for each of the periods were used as covariates.
Analysis of Treatment effects w For each time point, 7 hours and 24 
hours, the allergen challenge effect and the fp treatment effect were calculated. The 
allergen challenge effect (ace) was calculated as the change from baseline when the 
subject received placebo treatment. The fp treatment effect (fte) was calculated as 
the difference in change from baseline between the fp treatment group and the pla-
cebo group. P-values for each gene in each treatment effect were adjusted using the 
Benjamini-Hochberg’s procedure with a false discovery rate (fdr) level pre-speci-
fied at 0.025 to select significant genes.
correlation analyses w Pearson correlation coefficient and the associated 
p-value were computed for correlation between the estimated individual subject-
level effect, separately for allergen challenge effect and fp treatment effect, for a 
given clinical endpoint and gene of interest. Assuming no period or sequence effect, 
subject-level allergen challenge effect was calculated as the log-transformed change 
from baseline, for a clinical endpoint or gene of interest, when the subject received 
placebo treatment. Similarly, subject-level fp treatment effect was calculated as the 
difference in change from baseline for a clinical endpoint or gene of interest when 
the subject received fluticasone vs placebo. Type I error of 10% (two-sided) was used 
to select significant results, and no multiplicity adjustment was applied for declaring 
statistical significance.
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key inflammatory responses associated with allergic asthma, correlated with clinical 
endpoints and may constitute potential pd biomarkers of response to fluticasone.
th2 responses have been traditionally described as playing a central role in the 
pathophysiology of asthma, although not all patients share a th2 inflammatory 
pattern [31]. It is striking that in our study the shift toward the th2 differentiation 
pathway is a major element of the transcriptional response to the hdm challenge in 
sputum and is down regulated following response to fluticasone treatment in the 
mild asthmatic atopic subjects enrolled in this study. The implications of these re-
sults are several-fold. 
First, the screening of subjects for dual ear and lar responses and the strong 
homogeneity of our results are consistent with the concept of clustering of clinical 
asthma phenotypes in which presence of eosinophilic infiltration was identified as 
one of the key variables [32]. Furthermore, clinical phenotypes of asthma have been 
linked to molecular signatures and pathways in a study where th2 “high” and “low” 
phenotypes, characterized by differences in airway responsiveness, eosinophilia and 
airway remodeling, could be differentiated at the molecular level [33]. The observed 
low variability and high effect size obtained for the gene expression measurements 
in this study is likely due to the careful selection of a homogeneous allergic, cortico-
steroid responsive subject population characterized by eosinophilic inflammation in 
response to an allergen challenge.
Second, our results also suggest that gene expression measurements collected in 
such an allergen challenge platform could guide the development of novel quantita-
tive assays. For instance, one direct application of this technology could be the quan-
tification of the rnas that correlate the best with eosinophil numbers as a surro-
gate to the standard sputum eosinophil cell count assays. Another application of our 
technology would be the selection of pd biomarkers of response to anti-inflamma-
tory treatment in asthma identified from a set of markers that correlate with clinical 
endpoints. 
The results presented here also raised important questions. We identified from 
our data set two cytokines, il-22 and il-26, induced by the allergen challenge and 
reverted to baseline by fluticasone, which have been associated with the th17 path-
way. il-22 is preferentially produced by th17 cells in psoriatic skin and mediates the 
epithelium hyperplasia induced by il-23 [34]. il-26 is often co-expressed together 
with il-17 and il-22 by activation of th17 cells, however, its function remains to 
be further investigated [35]. Despite the significance of il-22 and il-26, we were 
however unable to detect any up or down-regulation of the cytokines il-17A and 
il-17 F, as well as other genes associated with the th17 pathway [36], therefore pro-
viding more support to the concept of a dominant th2 response in this study.
well as the generation of leukotrienes and prostaglandins; the messengers for the 
enzyme ggt5 (gamma glutamyl transferase 5, which converts leukotrienes C4 to 
D4) [30]; alox15 (15-lipoxygenase) and the receptor ptger3 (prostaglandin recep-
tor 3) were also up regulated by the allergen challenge and down regulated by fp 
treatment. In most of the cases, the fold change from baseline was higher at 7 hours 
versus 24 hours and the p-values smaller. This suggests that the 7 hours’ time point 
provides the most useful readouts of the strict inflammatory response following an 
allergen challenge.
In order to facilitate the correlation analyses, the union of the genes affected by 
the allergen challenge and fluticasone 7 hours or 24 hours post-challenge was re-
duced to a set of 47 rna signatures based on statistical significance, intensity of the 
change from baseline, biological relevance and classified based on druggable struc-
tural and functional categories (Figure 6). All the genes represented in the 47 rna 
signatures harbor robust expression changes, and the large majority of them is up-
regulated after 7 hours with the exception of flt3 and crlf2, which are regulated 
only after 24 hours.
The 47 rna signature set was then used to identify genes correlating with lung 
function measurements (Table 2) and eosinophil cell counts and percentages (Table 
3). Allergen challenge and fp treatment-mediated correlations were independently 
assessed for each probe set in the signature by estimating correlations at the subject 
level at 7 and 24 hours post allergen challenge. Correlation plots for the most signifi-
cant probe sets from each correlation analysis type are represented in Figure 7. High 
correlation for some of the probe sets, e.g. il1rl1 and hrh4 and the eosinophil 
counts from the allergen challenge and the fluticasone treatment effect were ob-
served, with correlation coefficients greater than 0.9 and p-value between < 0.001-
0.002. In the allergen challenge effect analysis, probe sets for nrg1, ccr2, cd1C, 
map2K6, il26 were negatively correlated with fev1 measurements at 7 hours. In the 
fluticasone treatment effect, probe sets for, nrg1, runx3, flt3, negatively correlated 
to the fev1 measurements at 7 hours and 24 hours. nrg1 was the most significant 
gene consistently negatively correlated to lung function measurements at 7 hours in 
both the allergen effect and the fluticasone effect analysis with p-values of and coef-
ficients of correlations in the range of -0.75 (p-value 0.054) to -0.90 (p-value 0.002).
discussion
In this study a rna signature in sputum induced by the allergen challenge and re-
versed with fluticasone was identified. A subset of these genes, known to regulate the 
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therapeutic approach for decreasing mucus hypersecretion in respiratory diseases. 
In conclusion, our rna extraction and profiling protocols allowed sensitive assess-
ments of allergen-induced inflammatory signatures in sputum and precise quanti-
fication of drug effects on this response in allergic asthmatics. This approach offers 
novel possibilities for development of pharmacodynamic biomarkers in asthma.
Another question is whether the observed signature in sputum is due to i) changes 
in cell counts, in particular eosinophil cell counts since this cell type is predominant-
ly increased in sputum following a segmental allergen challenge, ii) up or down-
regulation of messengers within a given cell type or, iii) a combination of the above. 
The only way to address this question is to profile individual cell types isolated from 
sputum, however, the results from our analysis indicated some changes in gene ex-
pression that were correlated with cell type specific eosinophil cell counts and some 
that are not, therefore supporting option iii). On the one hand, we have identified 
two genes il1rl1 and hrh4 that correlate extremely precisely with eosinophil cell 
counts (correlation coefficients > 0.9, p-values <0.002) and are known to be ex-
pressed predominantly in eosinophils, basophils and mast cells. rnas for both genes 
therefore appear to be excellent surrogates of eosinophil measurements in sputum. 
Interestingly, polymorphisms in the hrh4 gene were found to be associated with 
atopic dermatitis [37], while variants of the il1rl1 gene have been associated with 
atopic dermatitis and atopic asthma [38]. Given the important role that il1rl1 has 
in eosinophil function as a receptor for il-33, this gene might therefore also rep-
resent a promising drug target in inflammatory diseases characterized by a strong 
eosinophilic component correlating with disease symptoms. Then again, we have 
identified from this study multiple examples of genes that display similar expression 
pattern upon allergen challenge and fluticasone treatment and which are known to 
have very different cell type specificity. In particular chemokines ccl13 and ccl17 
have a dendritic specific expression while ccl26 is epithelial specific; similarly cd1A 
and cd1B are T-cell specific markers. However, as the expression of those genes is 
up-regulated by the allergen challenge and down-regulated by fluticasone, this sug-
gests that the identified signature cannot be explained uniquely by variations in eo-
sinophil cell counts or percentages and also reflects major transcriptional changes in 
a large variety of cell types. An analysis of the transcriptional signatures of isolated 
sputum cell types in combination with the identification of transcriptional modules 
of genes co-expressed in asthma as previously described in blood [39] could map the 
relative contribution of each gene and cell type to the inflammatory response.
Finally, we also identified from our analysis a set of rnas that uniquely correlates 
with classical lung function measurements. At 7 hours, chemokines or chemokine 
receptors (ccl13, ccl17, ccl26, and ccr2) and membrane bound glycoproteins such 
as cd1B, cd1C and cd209 correlate to lung function measurements. nrg1, the gene 
that most significantly correlated to fev1 measurements at 7 hours, is a member of 
the neuregulin family, which signals through tyrosine kinases of the ErbB3 family. 
nrg1 induces the expression of the globlet cell mucin proteins muc5ac and muc5B 
in human airway epithelium [40]. Its inhibition may therefore represent a novel 
Table 2 Correlations between gene expression measurements from the 47 rna signatures and various fev1 
measurements. fev1 measure i: % change in maximal drop of fev1 during lar, fev1 measure ii: % change in 
time weighed average of fev1 during lar, fevi measure iii: % change in fev1 at hour 24. Significant probe sets 
(p-values < 0.1 and correlation coefficient > 0.73) are displayed.
Effect of interest Probe set Gene 
symbol




















100150696_tgi_at nrg1 fevi Measure ii2 -0.90 (-0.98, -0.62) 0.002
100300593_tgi_at nrg1 fevi Measure ii2 -0.83 (-0.96, -0.44) 0.01
100124067_tgi_at ccr2 fevi Measure i1 -0.79 (-0.95, -0.32) 0.02
100312593_tgi_at nrg1 fevi Measure i1 -0.77 (-0.94, -0.28) 0.025
100161022_tgi_at cd1c fevi Measure ii2 -0.77 (-0.94, -0.27) 0.027
100303601_tgi_at ccr2 fevi Measure i1 -0.76 (-0.94, -0.26) 0.027
100145467_tgi_at cd1c fevi Measure ii2 -0.76 (-0.94, -0.26) 0.027
100161022_tgi_at cd1c fevi Measure i1 -0.76 (-0.94, -0.25) 0.03
100147484_tgi_at ccr2 fevi Measure ii2 -0.75 (-0.94, -0.24) 0.031
100300556_tgi_at map2k6 fevi Measure ii2 -0.75 (-0.94, -0.24) 0.03
100311406_tgi_at cd1c fevi Measure ii2 -0.74 (-0.93, -0.21) 0.036
100159528_tgi_at il26 fevi Measure ii2 -0.74 (-0.93, -0.21) 0.036








100135727_tgi_at cd1a fevi Measure ii2 0.87 ( 0.46,  0.97) 0.012
100127751_tgi_at nrg1 fevi Measure i1 -0.84 (-0.97, -0.39) 0.017
100302360_tgi_at nrg1 fevi Measure i1 -0.84 (-0.97, -0.37) 0.019
100155853_tgi_at runx3 fevi Measure i1 -0.77 (-0.95, -0.19) 0.044





fevi Measure i1 
fevi Measure iii3 
-0.75 (-0.95, -0.16) 
-0.74 (-0.91, -0.34) 
0.051
0.01
mrna at hour 7 and clinical endpoint at hour 24
Allergen challenge 
effect  
100148726_tgi_at ccl17 fevi Measure iii3 -0.80 (-0.95, -0.36) 0.016







100145401_tgi_at maoa fevi Measure iii3 0.80 ( 0.27,  0.96) 0.031
100301747_tgi_at adam19 fevi Measure iii3 0.80 ( 0.26,  0.96) 0.031
100127751_tgi_at nrg1 fevi Measure iii3 -0.75 (-0.95, -0.14) 0.054
100155853_tgi_at runx3 fevi Measure iii3 -0.74 (-0.94, -0.12) 0.058
100309572_tgi_at flt3 fevi Measure iii3 -0.74 (-0.94, -0.12) 0.058
mrna at hour 24 and clinical endpoint at hour 24
Allergen challenge 
effect   
100157709_tgi_at alox15 fevi Measure iii3 0.77 ( 0.28,  0.94) 0.025
100149346_tgi_at socs2 fevi Measure iii3 -0.75 (-0.94, -0.24) 0.031
 1% change in maximal drop of fev1 during lar; 2% change in time weighed average of fev1 during lar;  
3% change in fev1 at hour 24
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Table 1 Number of statistically significant probe sets identified from each contrast analysis, allergen 
challenge effect and fluticasone treatment effect, at 7 hours and 24 hours. The analysis was conducted on the 
whole microarray containing 50,159 human transcripts. The number of probe sets in common between the 
allergen challenge effect and the fluticasone effect analyses at a given time point are displayed on the right 
hand side. fdr: false discovery rate 
fdr < 0.025
# of probe sets in common
Allergen Challenge Effect (ace) at Hour 7 4,175 714
Fluticasone Treatment Effect (fte) at Hour 7 1,001
Allergen Challenge Effect (ace) at Hour 24 1,143 311
Fluticasone Treatment Effect (fte) at Hour 24 1,018
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Figure 1 Study design. Overview of the single-blind placebo run-in period and double blind cross-over study 
periods 1 and 2 (upper section). Overview of study assessments (lower section). Time zero is time of first study 
medication dosing. The single-blind placebo run-in screening period and the subsequent study periods 1 & 2 
were identical. is: induced sputum.
Figure 2 Hierarchal cluster assessment of sputum microarray data. Numbers refer to subject allocation 
numbers. Log 10 ratios of intensity estimates versus the average of all intensities are displayed. Dark color 
refers to probe sets that are up-regulated in reference to the pool of all specimens analyzed and light to the 
probe sets that are down-regulated. Left dark rectangles link specimens from the same subject that co-cluster 
on the dendrogram
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day i  day ii day iii














days of run in
Run in Period Period 1 Period 2 Poststudy
> 21 days wash out
interval
> 21 days wash out
interval
placebo placebo
active drug active drug








subject 4 baseline period 1
subject 4 baseline period 2
subject 3 baseline period 1
subject 3 baseline period 2
subject 11 baseline period 2
subject 6 baseline period 1
subject 6 baseline period 2
subject 1 baseline period 1
subject 1 baseline period 2
subject 12 baseline period 1
subject 5 baseline period 1
subject 5 baseline period 2
subject 11 baseline period 1
subject 10 baseline period 1
subject 10 baseline period 1
subject 12 baseline period 1
subject 13 baseline period 1
subject 13 baseline period 1
0     0,5     1
-0,3    0    0,3
Table 3 Correlations between the gene expression measurements from the 47 rna signatures and eosinophils 
(cell counts and percentages).Significant probe sets (p-values < 0.1 and correlation coefficients > 0.86) are 
displayed 
Effect of interest Probe set Gene 
symbol





mrna at hour 7 and clinical endpoint at hour 7
Allergen 
challenge effect
100302783_tgi_at il1rl1 Eosinophil counts 0.92 ( 0.70,  0.98) 0.001
100161010_tgi_at hrh4 Eosinophil counts 0.91 ( 0.67,  0.98) 0.002
  100149346_tgi_at socs2 Eosinophil counts 0.91 ( 0.66,  0.98) 0.002






0.88 ( 0.56,  0.97) 





100148162_tgi_at il1rl1 Eosinophil counts 0.98 ( 0.92,  1.00) < 0.001 
100312840_tgi_at il1rl1 Eosinophil counts 0.98 ( 0.88,  1.00) < 0.001 
  100302783_tgi_at il1rl1 Eosinophil counts 0.97 ( 0.85,  0.99) < 0.001 
  100142511_tgi_at ccl26 Eosinophil percentage 0.97 ( 0.84,  0.99) < 0.001 








































0.96 ( 0.79,  0.99) 
0.93 ( 0.69,  0.99) 
0.92 ( 0.64,  0.98) 
0.90 ( 0.59,  0.98) 
0.89 ( 0.52,  0.98) 
0.88 ( 0.52,  0.98) 
0.88 ( 0.52,  0.98) 
0.88 ( 0.51,  0.98) 
0.88 ( 0.51,  0.98) 
0.88 ( 0.50,  0.98) 
0.87 ( 0.48,  0.97) 
0.87 ( 0.46,  0.97) 

























0.87 ( 0.55,  0.97) 










100148210_tgi_at il1rl1 Eosinophil counts 0.93 ( 0.67,  0.99) 0.003
100309438_tgi_at maoa Eosinophil counts -0.92 (-0.98, -0.64) 0.003
100309708_tgi_at ptgs1 Eosinophil counts 0.92 ( 0.65,  0.98) 0.003










0.89 ( 0.53,  0.98) 
0.88 ( 0.51,  0.98) 
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Figure 4 Fold change from baseline in gene expression. Th2 cytokines (il4, il5, il13), Th1 cytokines (ifng 
and tnf), Th17 cytokines (il22, il26). Fold change from baseline for the placebo group is represented on the 
left in each bar. Fold change from baseline for the fluticasone group is represented on the right in each bar. 
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Figure 3 Log 10 Estimates of gene expression changes for the significant genes identified from contrast 
analysis at 7 hours and 24 hours with an fdr < 0.025. ace; allergen challenge effect, estimates of changes from 
baseline in the placebo group. fte: fluticasone effect, estimates of differences in change from baseline between 
the placebo and the fluticasone groups




























24h (311 probe sets)
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Figure 6 Fold changes over baseline (point estimate and 90% confidence intervals) for the 47 rna signatures. 
Light bars represent the change from baseline in the placebo group and dark bars in the fluticasone group. 
P-values for the allergen challenge effect (ace) and the fluticasone treatment effect (fte) are represented.  
P1: Th2 cytokines, P2: chemokines and chemokine receptors, P3: fceri and histamine signaling, P4: enzymes 
and signaling molecules in prostaglandin, leukotriene pathways, P5: Other cytokines, growth factors and their 
receptors, P6: Other enzymes, P7: membrane bound glycoproteins, P8: transcription factors, P9: regulators  
of the inflammatory response"
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Figure 5 Fold change from baseline in gene expression. Inflammatory chemokines (ccl13, ccl17, ccl26), 
molecules controlling the release of histamine (hdc, hrh4, fcer1a) prostaglandins and leukotrienes (ptger3, 
alox15, ggt5). Fold change from baseline for the placebo group is represented on the left in each bar. Fold 
change from baseline for the fluticasone group is represented on the right in each bar. P-values are adjusted 
p-values, error bars represent 90% confidence intervals.
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Figure 7 Correlation plots of the most significant probe sets to individual subject clinical measurements for 
the allergen challenge effect and the fp treatment effect. Correlation coefficients and corresponding p-values 
in parenthesis are listed in grey. hrh4 (histamine receptor 4); il1rl1 (il33 receptor); nrg1 (neuregulin 1)
reference list
1 Diamant Z, Gauvreau GM, Cockcroft DW et al. 
Inhaled allergen bronchoprovocation tests. J Allergy 
Clin Immunol. 2013; 132: 1045-1055
2 Boulet LP, Gauvreau G, Boulay ME, O'Byrne P, 
Cockcroft DW. The allergen bronchoprovocation 
model: an important tool for the investigation of new 
asthma anti-inflammatory therapies. Allergy 2007; 62: 
1101-1110
3 Bakakos P, Schleich F, Alchanatis M, Louis R. Induced 
sputum in asthma: from bench to bedside. Curr Med 
Chem. 2011; 18: 1415-1422
4 Gauvreau GM, Watson RM, O'Byrne PM. Kinetics of 
allergen-induced airway eosinophilic cytokine produc-
tion and airway inflammation. Am J Respir Crit Care 
Med 1999; 160: 640-647
5 Diamant Z, Timmers MC, van d, V, Page CP, van 
der Meer FJ, Sterk PJ. Effect of inhaled heparin on 
allergen-induced early and late asthmatic responses 
in patients with atopic asthma. Am J Respir Crit Care 
Med 1996; 153: 1790-1795
6 Parameswaran K, Inman MD, Watson RM et al. 
Protective effects of fluticasone on allergen-induced 
airway responses and sputum inflammatory markers. 
Can.Respir J 2000; 7: 313-319
7 Zuiker RG, Ruddy MK, Morelli N et al. Kinetics of 
th2 biomarkers in sputum of asthmatics following 
inhaled allergen. Eur Clin Respir J 2015; 2
8 Faiz A, Burgess JK. How can microarrays unlock 
asthma? J Allergy (Cairo.) 2012; 2012: 241314
9 Rolph MS, Sisavanh M, Liu SM, Mackay CR. Clues 
to asthma pathogenesis from microarray expression 
studies. Pharmacol Ther 2006; 109: 284-294
10 Lee JH, Kaminski N, Dolganov G et al. Interleukin-13 
induces dramatically different transcriptional programs 
in three human airway cell types. Am J Respir Cell Mol 
Biol 2001; 25: 474-485
11 Lilly CM, Tateno H, Oguma T, Israel E, Sonna LA. 
Effects of allergen challenge on airway epithelial cell 
gene expression. Am J Respir Crit Care Med 2005; 171: 
579-586
12 Laprise C, Sladek R, Ponton A, Bernier MC, Hudson 
TJ, Laviolette M. Functional classes of bronchial mu-
cosa genes that are differentially expressed in asthma. 
BMC Genomics 2004; 5: 21
13 Guajardo JR, Schleifer KW, Daines MO et al. Altered 
gene expression profiles in nasal respiratory epithelium 
reflect stable versus acute childhood asthma. J Allergy 
Clin Immunol. 2005; 115: 243-251
14 Singh A, yamamoto M, Kam SH et al. Gene-
metabolite expression in blood can discriminate 
allergen-induced isolated early from dual asthmatic 
responses. PLoS One 2013; 8: e67907
15 Goleva E, Hauk PJ, Hall CF et al. Corticosteroid-
resistant asthma is associated with classical antimicro-
bial activation of airway macrophages. J Allergy Clin 
Immunol 2008; 122: 550-559
16 Peters MC, Mekonnen ZK, yuan S, Bhakta NR, 
 Woodruff PG, Fahy JV. Measures of gene expression 
in sputum cells can identify th2-high and th2-low 
subtypes of asthma. J Allergy Clin Immunol. 2014; 133: 
388-394
17 From the Global Strategy for Asthma Management 
and Prevention, Global Initiative for Asthma (gina). 
Available from: http://www.ginasthma.org/ [cited 4 Jan 
2016].  2015. 
18 ats/ers recommendations for standardized procedures 
for the online and offline measurement of exhaled lower 
respiratory nitric oxide and nasal nitric oxide. Am J 
Respir.Crit.Care Med 2005; 171: 912-930
19 Crapo RO, Casaburi R, Coates AL et al. Guidelines  
for methacholine and exercise challenge testing-1999. 
This official statement of the American Thoracic 
Society was adopted by the ats Board of Directors,  
July 1999. Am J Respir Crit Care Med 2000; 161: 
309-329
20 Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. 
Standardised methodology of sputum induction and 
processing. Eur Respir J Suppl. 2002; 37: 1s-2s
21 Miller MR, Hankinson J, Brusasco V et al. 
Standardisation of spirometry. Eur Respir J 2005; 26: 
319-338
22 Pizzichini E, Pizzichini MM, Leigh R, Djukanovic R, 
Sterk PJ. Safety of sputum induction. Eur Respir  
J Suppl. 2002; 37: 9s-18s
23 Efthimiadis A, Spanevello A, Hamid Q et al. 
Methods of sputum processing for cell counts, 
immunocytochemistry and in situ hybridisation. Eur 
Respir J Suppl. 2002; 37: 19s-23s
24 Eisen MB, Spellman PT, Brown PO, Botstein D. 
Cluster analysis and display of genome-wide expression 
patterns. Proc Natl Acad Sci usa 1998; 95: 14863-14868
25 Mendez-Enriquez E, Garcia-Zepeda EA. The 
multiple faces of ccl13 in immunity and inflammation. 
Inflammopharmacology. 2013; 21: 397-406
26 Sekiya T, yamada H, yamaguchi M et al. Increased 
levels of a th2-type cc chemokine thymus and 
activation-regulated chemokine (tarc) in serum and 
induced sputum of asthmatics. Allergy 2002; 57: 173-177
27 Larose MC, Chakir J, Archambault AS et al. 
Correlation between ccl26 production by human 
bronchial epithelial cells and airway eosinophils: 
Involvement in patients with severe eosinophilic 
asthma. J Allergy Clin Immunol 2015; 136: 904-913
28 Ohtsu H. Pathophysiologic role of histamine: evidence 
clarified by histidine decarboxylase gene knockout 
mice. Int Arch Allergy Immunol 2012; 158 Suppl 1: 2-6
29 Hartwig C, Munder A, Glage S et al. The histamine H4 
-receptor (h4 r) regulates eosinophilic inflammation 
in ovalbumin-induced experimental allergic asthma in 
mice. Eur J Immunol 2015; 45: 1129-1140
30 Han B, Luo G, Shi ZZ et al. Gamma-glutamyl 
leukotrienase, a novel endothelial membrane protein, is 
specifically responsible for leukotriene d(4) formation 
in vivo. Am J Pathol 2002; 161: 481-490
 
 
section 1 – biomarker development and evaluation 
∂ 66 ∂
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
w w w w w w w w w w w w w w w 
31 Gauthier M, Ray A, Wenzel SE. Evolving Concepts of 
 Asthma. Am J Respir Crit Care Med 2015; 192: 660-668
32 Haldar P, Pavord ID, Shaw DE et al. Cluster analysis 
and clinical asthma phenotypes. Am J Respir Crit Care 
Med 2008; 178: 218-224
33 Woodruff PG, Modrek B, Choy DF et al. t-helper type 
2-driven inflammation defines major subphenotypes of 
asthma. Am J Respir Crit Care Med 2009; 180: 388-395
34 Zheng y, Danilenko DM, Valdez P et al. 
Interleukin-22, a T(H)17 cytokine, mediates il-23-in-
duced dermal inflammation and acanthosis. Nature 
2007; 445: 648-651
35 Donnelly RP, Sheikh F, Dickensheets H, Savan R, 
young HA, Walter MR. Interleukin-26: an IL-10-
related cytokine produced by th17 cells. Cytokine 
Growth Factor Rev 2010; 21: 393-401
36 Newcomb DC, Peebles RS, Jr. th17-mediated in-
flammation in asthma. Curr Opin Immunol 2013; 25: 
755-760
37 yu B, Shao y, Zhang J et al. Polymorphisms in human 
histamine receptor h4 gene are associated with atopic 
dermatitis. Br J Dermatol. 2010; 162: 1038-1043
38 Reijmerink NE, Postma DS, Bruinenberg M et al. 
Association of il1rl1, il18r1, and il18rap gene clus-
ter polymorphisms with asthma and atopy. J Allergy 
Clin Immunol 2008; 122: 651-654
39 Chaussabel D, Quinn C, Shen J et al. A modular analy-
sis framework for blood genomics studies: application 
to systemic lupus erythematosus. Immunity 2008; 29: 
150-164
40 Kettle R, Simmons J, Schindler F et al. Regulation of 
neuregulin 1beta1-induced muc5ac and muc5b ex-
pression in human airway epithelium. Am J Respir Cell 







exhaled nitric  




Rob GJA Zuiker [1*], Catherine Tribouley [2,3*],  
Zuzana Diamant [1,4], J. Diderik Boot [1,5], Adam  
F Cohen [1], K. Van Dyck [2], I. De Lepeleire [2], 
Veronica M Rivas [2],Vlad Malkov [2] , Jacobus 
Burggraaf [1], and Marcella K Ruddy [2,6].
*both authors contributed equally 
1. Centre for Human Drug Research, Leiden,
2. Merck Research Laboratories, New Jersey, usa  
and Brussels Belgium
3. Present affiliation: Novartis, New york, usa
4. Dept. of Respiratory  Medicine and Allergology, 
Lund, Sweden and University Medical Center 
Groningen, Dept. of Clinical Pharmacy & 
Pharmacology and Dept. of General Practice  
and qps, Groningen
5. Present affiliation: Janssen Biologics b.v., Leiden, 
6. Present affiliations: emd Serono, Rockland, 
Massachusetts, usa
Respiratory Medicine 2010 Jun; 104(6):917-20
chapter 4 – sputum induction in chronic smokers and non-smokers
∂ 69 ∂
section 1 – biomarker development and evaluation 
∂ 68 ∂
introduction
Sputum induction by hypertonic saline (si) and fractional exhaled nitric oxide 
(feno) are validated, commonly used non-invasive biomarker sampling methods of 
the lower airways [1;2]. feno measurements are increasingly applied for diagnosis 
and monitoring of asthma [3]. Furthermore, both methods are often used as com-
plementary research tools to assess the airway inflammation in response to interven-
tions with (novel) anti-inflammatory therapeutic modalities [4]. However, there is 
evidence that sampling methods sometimes interfere and thus may affect the levels 
of biomarkers [5]. So far, two published studies have addressed the effect of si on 
feno values in asymptomatic atopic subjects and asthmatic patients and showed a 
maximal decrease in feno directly post-induction with still a substantial decrease 
up to 4 hours after si [6;7]. In this study population, feno levels were reproducible 
and unrelated to the initial si-induced decrease in fev1 [6;7]. So far, few data have 
been published on chronic smokers [8;9]. Therefore, we tested the reproducibility 
and differences in feno levels between asymptomatic chronic smokers and healthy 
non-smokers. Furthermore, we investigated the effect of si on feno levels in both 
study groups.
methods
Subjects w The study population consisted of two groups: 16 asymptomatic 
chronic smokers with a smoking history of at least 10 pack-years (8F/8M; 32-52 
years) and 16 healthy non-smokers (8F/8M; 30-49 years) who had not smoked for at 
least 12 months prior to study enrolment and who had a total smoking history of less 
than 5 pack-years. For the smoker group, the last cigarette was smoked at least one 
hour before any study procedure. All subjects had no history of relevant lung disease 
or any respiratory tract infection for at least 4 weeks before the start of the study. 
All subjects gave written informed consent. The study was approved by the Ethics 
Committee of Leiden University Medical Centre, Leiden, Netherlands. 
Study design w The study comprised two study days, 4 to 10 days apart. On 
each study day, feno was measured approximately 55 minutes before and 30 minutes 
after the si-procedure. All assessments were performed at the same time of the day 
(± 2 h). This study was conducted as part of a larger biomarker study; the focus of 
this manuscript is on methodological issues related to the interaction of si on feno 
levels. 
abstract 
background Nitric oxide (no) measurements in exhaled air and hypertonic 
saline-induced sputum are commonly used biomarker sampling methods of the 
lower airways. Both sampling methods have been validated in asthmatic patients 
and healthy controls, however, data from chronic smokers are scarce.
objectives To evaluate the reproducibility and differences in fractional ex-
haled no (feno) values in asymptomatic chronic smokers and healthy, non-smok-
ing controls. Furthermore, to test the effect of hypertonic saline sputum induction 
(si) on feno levels in both study groups.
Methods 16 asymptomatic chronic smokers and 16 non-smokers participated 
in this study. Baseline feno and forced expiratory volume in 1 s (fev1) were recorded 
pre- and 30 min post-NaCl 4.5% si (3 x 5 min) on 2 study days (± 2 h; 4-10 days 
apart). Mixed anova was used to estimate the intra-subject Coefficient of Variation 
(cv) % over days; changes in feno and fev1 values before and after si, were analyzed 
by a Student’s paired t-test. The difference between smokers and non-smokers was 
estimated by a Student’s t-test.
results On day 1, feno values in smokers were significantly lower than in non-
smokers, 10.6 ppb, and 18.4 ppb, respectively, (42% difference, p = 0.0028, 95% ci: 
-59%, -19%). In both study groups, feno measurements were reproducible, with an 
intra-subject cv of 27.2% and 19.2%, for smokers and non-smokers, respectively. si 
significantly decreased feno levels in both study groups on day 1. In smokers, there 
was a mean reduction in feno of almost 37% (p<0.01, 95% ci (-53.2%, -14.2%), and in 
non-smokers a mean decrease of almost 35% (p=0.047, 95% ci -57%, -0.6%). In both 
study groups si did not affect fev1 (p>0.94).
conclusions Our data extend previous findings in asthmatics and healthy 
controls to asymptomatic chronic smokers: 1. feno measurements are reproducible 
in both smokers and non-smokers; 2. baseline feno levels in chronic smokers are 
lower than in non-smokers and 3. sputum induction by hypertonic saline reduces 
feno levels in both study groups, without affecting lung function.
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effect of sputum induction on feno and fev1 w On day 1, si de-
creased feno levels in non-smokers by on mean 35% (95% ci: -57%, -0.6%; p=0.047) 
and in smokers by on mean 37% (95% ci:-53%, -14%; p = 0.0045) (Table 2). si did not 
affect fev1 in either study group.
Discussion 
In line with previous observations in allergic asthmatics, we found reproducible 
feno levels in asymptomatic chronic smokers and healthy non-smoking controls. In 
smokers, feno levels were generally lower than in non-smokers and within similar 
ranges as previously reported [11]. Similarly to previous observations in allergic asth-
matics [6], hypertonic saline decreased feno levels in both study groups without af-
fecting fev1. Therefore, our findings confirm and extend previous data (5-7;12). 
The sputum inductions in our study were performed according to standardized 
procedures [1] in age- and gender-matched populations, while in the smokers the 
time between smoking and any measurements was kept within the same ranges [12]. 
Hence, the lack of statistical significance between both study groups and pre- and 
post-si on study day 2 is most probably due to a larger variability of the feno values 
in a small sample size, possibly caused by external factors. 
In line with previous studies we found lower feno levels in smokers compared 
with non-smokers [12]. It appears that smoking inhibits no formation from induc-
ible nitric oxide synthase in epithelial lung cells [13]. Furthermore, no synthesis may 
be reduced by negative feedback as a result of high no-concentrations in cigarette 
smoke [12], no oxidation or interaction with other molecules present in tobacco 
smoke [14]. 
In conclusion, feno levels in chronic smokers were found to be reproducible and 
generally lower than in healthy non-smokers. Sputum induction reduced feno in 
both study populations without affecting fev1. Our data extend previous observa-
tions in allergic asthmatics to chronic smokers. In view of the interference of spu-
tum induction with feno measurements: feno should be measured before sputum 
induction.
fractional exhaled nitric oxide (feno) w feno measurements 
were performed by a chemiluminescence analyser (Ecomedics cld88sp, Ecomedics, 
Duernten, Switzerland) according to current guidelines [1]. Briefly, after a deep in-
halation of no-free air, subjects exhaled for approximately 10 seconds against a resis-
tance at a stable flow of approximately 50 mL/s. The mean of the first three techni-
cally acceptable measurements (within 10%) were included in the analysis and ex-
pressed in parts per billion (ppb).
Pulmonary function tests w Spirometry was performed according to 
standardized protocols by a calibrated spirometer (Vmax Spectra Sensor Medics; 
Cardinal Health, Houten, The Netherlands) [10] connected to a personal computer. 
The mean of the two out of three (within 5%) highest, technically satisfactory 
forced expiratory volume in 1 second (fev1) measurements was included in the 
analysis.
Hypertonic saline sputum induction w Sputum was induced by hy-
pertonic saline (4.5% NaCl) nebulised by an ultrasonic nebulizer (DeVilbiss Ultra 
neb 2000, Somerset, pa, usa) according to current guidelines during three periods 
of 5 min each [2]. Spirometry was performed 7 minutes after each si-period.
Analysis w The reproducibility of the feno levels in both study groups was as-
sessed on log-transformed data by a Mixed Analysis of Variance (anova) to esti-
mate the intra-subject Coefficient of Variation (cv). The differences in feno levels 
between both study populations were analyzed with a Student’s t-test and the effect 
of inhaled NaCl 4.5% on feno and fev1 within both study groups was analysed 
with the paired Student’s t-test. Results were back-transformed to ratios and ex-
pressed as percentage difference.
Results
Study subjects w The study groups were well-matched with no statistically 
significant differences in baseline characteristics between the two groups (Table 1).
reproducibility and difference in feno between study 
groups w The intra-subject mean cv for baseline feno measurements was 19.2% 
and 27.2% for non-smokers and smokers, respectively (Table 2). Mean feno was sig-
nificantly lower in smokers compared with non-smokers. 
Table 2 Effect of si on feno and fev1 values
 


























































Coefficient of variation (cv%)  
for feno (pre nacl 4.5%)
non-smokers 19.2%
smokers 27.2%
 ci = confidence interval. feno values in geometric means; cv = coefficient of variation
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Table 1 Subjects’ baseline characteristics 
Non-smokers Smokers
Number of subjects 16 16
Age (years) 41 (30-49) 41 (32-52)
Gender (M/F) 8M/8F 8M/8F
Height (meters) 1.75 (1.56-1.93) 1.73 (1.58-1.85)
Weight (kg) 77.5 (51.8-110.2) 73.1 (46.5-100.5)
bmi (kg/m2) 25.1 (21.1-29.5) 24.3 (18.6-30.0)
fevi (L) 3.66 (2.75-5.16) 3.55 (2.38-4.64)
fevi (% predicted) 102.9 (78-119.6) 102.7 (82.1-121.1)
fvc (L) 4.78 (3.21-6.42) 4.46 (3.15–6.38)
fvc (% predicted) 105.1 (82-131) 111.7 (76-127)
Values presented as mean (range)
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early as possible in the course of the disease and undoubtedly before disability be-
comes substantial. Better understanding of the early pathophysiological changes in 
copd caused by smoking and the identification of relevant biomarkers may facili-
tate selection of appropriate molecular targets for pharmacological intervention [2]. 
Ideally, the identification of such biomarkers should be broadly applicable in the 
clinical setting and be non-invasive. 
Spirometry is a non-invasive method often used as primary endpoint for effi-
cacy in pharmacology studies as it provides information on the early physiological 
changes in smokers without copd. However, it does not provide information about 
the underlying pathology. Sputum induction is another non-invasive method and 
samples cellular and biochemical constituents of the lower respiratory tract allowing 
study of asthma and copd [3]. Analysis of induced sputum may focus on cell counts 
as an index of inflammation [4], but also sampling of soluble biomarkers in induced 
sputum from diseased airways has shown promise [5]. Indeed, in copd several types 
of biomarkers like interleukin 8 (il-8), leukotriene B-4 (ltb-4) and tumor necrosis 
factor-α (tnf-α) amongst others, have been measured in induced sputum that are 
thought to be related to inflammatory process and disease pathology [6]. Despite 
these findings, it has been recognized that only few of these biomarkers have been 
validated and that there is little information about reproducibility and the relation-
ship to disease development, severity or progression [7].
Therefore, we performed a clinical study in asymptomatic chronic smokers and 
healthy (non-smoking) controls to test reproducibility and differences in a set of 
soluble inflammatory markers in the supernatant of induced sputum and in serum. 
The inflammatory markers were chosen because of their presumed role in the 
pathogenesis of copd. Amongst other markers, the selection included il-8 repre-
senting T helper 1 (th1) driven inflammation; eosinophil derived neurotoxin (edn) 
and eotaxin representing th2 driven inflammation, and serum amyloid A (saa), 
and pulmonary surfactant associated protein D (spd) as markers reflecting inflam-
mation in general. From the same study two manuscripts dealing with methodolog-
ical aspects have been published [8;9].
Material and methods
Study design w The study consisted of two identical study days separated by 4- 
10 days. On each study day, eligible subjects underwent in sequential order: spirom-
etry, sputum induction and blood sample drawings. All assessments were performed 
at the same time of the day (± 2 h) on both study days. The study was performed 
Abstract
Rationale Soluble inflammatory markers obtained from non-invasive airway 
sampling such as induced sputum may be useful biomarkers for targeted pharma-
ceutical interventions. However, before these soluble markers can be used as poten-
tial targets, their variability and reproducibility need to be established in distinct 
study populations.
objective This study aimed to assess the reproducibility of biomarkers ob-
tained from induced sputum and serum in chronic smokers and non-smokers.
method Sputum and serum samples were obtained from 16 healthy non-
smokers and 16 asymptomatic chronic smokers (for both groups: 8M/8F, 30-52 
years, fev1 ≥80% pred.; ≥10 pack years for the smokers) on 2 separate visits 4-10 days 
apart. Soluble markers in serum and sputum were analyzed by elisa. The differ-
ences between smokers vs non-smokers were analyzed with a t-test and variability 
was assessed on log-transformed data by a mixed model anova.
results Analyzable sputum samples could be obtained from all 32 subjects. In 
both study populations neutrophils and macrophages were the predominant cell 
types. Serum Pulmonary Surfactant Associated Protein D had favorable repro-
ducibility criteria for reliability ratio (0.99), intra-subject coefficient of variation 
(11.2%) and the Bland Altman limits of agreement. Furthermore, chronic smokers, 
compared to non-smokers, had significantly higher sputum concentrations of il-8 
(1094.6 pg/mL vs 460.8 pg/mL, p=0.006)), and higher serum concentrations of 
Pulmonary Surfactant Associated Protein D (110.9 pg/mL vs 64.7 pg/mL, p=0.019), 
and lower concentrations of Serum Amyloid A (1352.4 pg/mL vs 2297.5 pg/mL, p= 
0.022). 
conclusion Serum Pulmonary Surfactant Associated Protein D proved to be 
a biomarker that fulfilled the criteria for reproducibility in both study groups.
introduction
Smoking is a known risk factor for the development of chronic obstructive pulmo-
nary disorder (copd) and asymptomatic chronic smokers (without signs of copd) 
already show evidence of airway inflammation [1]. Patients should be identified as 
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Minnesota, usa). For each analyte the coefficient of variation was < 10% for both 
inter and intra assay variability.
Statistical analysis w Because of the exploratory nature of the study, a 
power calculation to determine the sample size was not performed. 
Markers were excluded from analyses if ≥50% of the dataset for a soluble marker was 
outside the quantification range, or when paired data were available in less than five 
subjects (Table 1). 
For the purposes of this manuscript, reproducibility is defined as the consistency 
of results derived from the elisa analysis of incurred samples on two independent 
study days. Each soluble mediator was summarized (mean) by study day and study 
group. Variability per soluble mediator was evaluated by intra-subject coefficient of 
variation (calculated by a mixed analysis of variance model) and by the reliability 
ratio (variance due to subjects /(variance due to subjects + variance due to residu-
al)). Reproducibility for soluble inflammatory markers was evaluated with the val-
ues measured on study days 1 and 2 with Bland Altman method [13;14]. The mean 
ratio of the sample results, along with its 95% confidence interval expressed as Ratio 
Limit (rl), was taken as a measure for accuracy. The interval for a 25% systematic 
difference was 0.8 to 1.25. For measuring precision, the Limit of Agreement (la) was 
calculated as la = ed±sd, where d is the mean difference between two sampling days 
on log-scale, and sd is the standard deviation of the differences on log-scale. la was 
defined as being equivalent to mean ± sd, which indicates that about 68% of all pairs 
of test data would be within the acceptance range [14].
Results
Subjects w All subjects completed both study days and all study procedures 
were well tolerated. There were no significant differences in demographics and base-
line lung function parameters, as measured by fev1 and fvc, between chronic smok-
ers and non-smokers, Table 2.
Reproducibility of sputum biomarkers w In both study populations 
neutrophils and macrophages were the predominant cell types, Table 3. No mast cells 
were found in any of the samples. There was no significant difference between day 1 
and day 2 for any of the cell types in each study group. The intra-subject variability 
was the lowest for eosinophils and neutrophils in both groups. There were no signifi-
cant differences in cell types between the two groups. 
at the Centre for Human Drug Research (chdr) in Leiden, the Netherlands and 
approved by the Ethics Committee of Leiden University Medical Centre, Leiden, 
Netherlands. All subjects provided written informed consent.
Subjects w Two groups of 16 subjects each were included in the study and 
matched for gender and age: asymptomatic chronic smokers with a smoking history 
of at least 10 pack-years (8F/8M) and healthy non-smokers (8F/8M). Non-smoking 
was defined as: no smoking for a minimum of 12 months prior to study enrolment 
and less than 5 pack-years of smoking history. For the chronic smoker group, the last 
cigarette was smoked more than one hour before any study procedure. None of the 
subjects in both study groups had had any history of relevant lung disease or respira-
tory tract infection for at least 4 weeks before the start of and during the study. 
Sputum induction procedure w Sputum induction was performed as 
previously described [10;11] using a DeVilbiss Ultraneb 2000 ultrasonic nebulizer 
(Tefa Portanje, Woerden, The Netherlands) connected to a 100-cm long plastic 
tube, with an internal diameter of approximately 22 mm, connected to a two-way 
valve (No.2700; Hans-Rudolf, Kansas City, mo, usa) with a mouthpiece. After 200 
μg of salbutamol was administered, hypertonic saline (NaCl 4.5%) was nebulised 
and inhaled through the mouth, with the nose clipped, during three periods of 5 
minutes. Before the start of the procedure and at approximately 7 minutes following 
each induction, spirometry was performed as a safety measure.
Sputum processing w The cell pellet of was processed as a full sample ac-
cording to guidelines [10;12], using 0.1% dithiothreitol (dtt) (Sputolysin, 
Calbiochem, La Jolla, ca, usa). Cell viability and total cell count were assessed using 
Trypan Blue; sputum samples containing > 80 % squamous cells were excluded from 
analysis. Leucocyte differential cell counts (eosinophils, lymphocytes, macrophage 
and neutrophils) were performed by a qualified cytologist on May-Grünwald-
Giemsa stained coded cytospins. Cell differentials were counted on 500 nucleated 
nonsqamous cells and expressed as percentage.
Biochemical assays w The panel of markers measured in sputum superna-
tant and serum consisted of eosinophil derived neurotoxin (edn), fibronectin, inter-
leukin 8 (il-8), interleukin 17, (il-17), monocyte chemotactic protein-1 (edn), serum 
amyloid A (saa), pulmonary surfactant associated protein D (spd), transforming 
growth factor beta 1 (tgf-b1), eotaxin and thymus and activation regulated chemo-
kine (tarc). All markers were analysed with elisa (R&D systems, Minneapolis, 
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The higher concentrations of il-8 in chronic smokers compared to the non-smoker 
group, confirmed previously reported data [5;18;19]. Indeed, inhibition of il-8 or its 
receptors is a potential target for copd treatment. Although several compounds are 
currently in clinical development, so far il-8 specific antibodies have been largely 
ineffective in copd. Similarly, an il-8 receptor antagonist reduced sputum neutro-
phils in patients with copd, but larger studies showed no clinical benefit [20;21].
Our finding on the serum concentrations of saa was remarkable as non-smok-
ers showed higher levels compared to smokers. saa is an apolipoprotein and acute 
phase protein predominantly produced by the liver and it is related to neutrophil 
chemotaxis. In copd patients during acute exacerbations elevated saa levels been 
reported [22]. The relevance of this finding is not straight forward as also relatively 
trivial inflammatory stimuli can lead to rapid saa responses [23]. Nevertheless our 
findings are at odds with previous reports [24;25] showing higher level of saa in 
smokers, for which we have no explanation. 
In this study some of the soluble sputum biomarkers were not detectable or did 
not differentiate between the study groups. One accountable factor includes the 
degradation by standard sputum processing with dithiothreitol (dtt), which de-
stroys the disulphide bounds of these inflammatory markers [26]. Another obser-
vation is the relative neutrophilia in the differential cell count from non-smokers, 
while in other studies macrophages were the predominant cell type in induced spu-
tum [27-29]. This relative neutrophilia in the non-smokers could not be explained by 
the influence of outliers nor a recent colds [30] as the latter was an exclusion crite-
rion for the study. Nevertheless, it may be that the seasonal and environmental fac-
tors [31], the study was conducted in winter, are reflected in this observation. On the 
other hand, the predominance of neutrophils in chronic smokers, corresponds well 
with other studies in similar populations [5;32]. 
Selection of the inflammatory markers in this study was based on a hypothesis- 
dependent approach in which markers that may be involved in the pathophysiol-
ogy of copd were selected and analysed. An alternative strategy would have been an 
unbiased approach e.g. not based on known pathways only. This could for example 
be achieved by large scale analysis of proteins (proteomics) or metabolites (metabo-
lomics). Such studies have shown to result in protein fingerprints, which potentially 
could be used to investigate the pathophysiology of copd in more detail, stratify 
patients for the treatment of copd and provide a tool to therapy response [33;34]. 
Despite these promising results, it is important to realize that also this type of bio-
markers should properly be validated and preferably underpinned by a mechanistic 
understanding of the changes in these profiles, before they can be utilized reliably as 
markers for disease progression or assessment of treatment effects. This may become 
Analysable sputum samples could be obtained from all 32 subjects at both visits. 
Only 4 soluble markers, eosinophil derived neurotoxin (edn), Interleukin-8 (il-8), 
monocyte chemotactic protein-1 (mcp-1) and prostaglandin E2 (pge2) met the cri-
teria for analysis. None of those markers met the criteria for reproducibility. il-8 
was significantly higher in chronic smokers compared to non-smokers on day 1 (p = 
0.006) and on day 2 (p = 0.026), Table 4. 
Reproducibility in serum w In serum 8 markers (eotaxin, fibronectin, 
edn, edn, saa, spd, tarc and tgfb1) met the criteria for analysis. spd in serum 
was significantly higher (p = 0.02) in chronic smokers compared to non-smokers on 
both study days (Table 4) and met the criteria for reproducibility when comparing 
day 1 and 2 in both study groups. Eotaxin was reproducible in chronic smokers and 
transforming tgfb1 was reproducible in non-smokers. In addition, saa was signifi-
cantly lower in chronic smokers compared to non-smokers on both study days (p= 
0.022 and p = 0042, resp.), Table 5.
Discussion
Cellular and soluble sputum biomarkers and biomarkers obtained in serum from 
16 asymptomatic chronic smokers and 16 non-smokers were measured and investi-
gated for reproducibility. spd concentration fulfilled the criteria for reproducibility 
and that chronic smokers compared to non-smokers had significant higher concen-
trations of il-8 in induced sputum and lower concentrations of saa.
spd in serum showed a two fold increase in chronic smokers compared to non-
smokers. spd is mainly produced by type 2 pneumocytes and non-ciliated bronchio-
lar cells. Smoking reduces the amount of spd in the bronchoalveolar lavage fluid, 
probably as a result of spd leakage through the pulmonary epithelium into the sys-
temic circulation, but increases spd serum levels [15]. These increases in serum are 
apparently independent of age and smoking history but dependent with the degree 
of airway obstruction [16].
spd is the only biomarker in this study that showed significant reproducibility 
in both the chronic smokers and the non-smoking group. Both the intra-subject 
coefficient of variation (11.2%) and the Bland Altman limits of agreement indicated 
reproducibility. These properties in addition to its association with exacerbations of 
copd [17] and its quality to discriminate significantly between the chronic smokers 
and non-smokers may make it an attractive lung specific biomarker or drug target in 
copd.
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Table 1 Overview of collected markers
Matrix Population Soluble 
Mediator
% Data >lloq 
and >uloq




Serum Non-Smoker edn 96.875 15 yes
Fibronectin 100 16 yes
il-8 6.25 0 No
edn 100 16 yes
saa 100 16 yes
spd 93.75 15 yes
tgfb1 100 16 yes
Eotaxin 100 16 yes
tarc 93.75 14 yes
Smoker edn 96.667 14 yes
Fibronectin 96.667 15 yes
il-8 12.5 0 No
edn 96.875 15 yes
saa 84.375 13 yes
spd 96.667 14 yes
tgf_b1 93.75 14 yes
Eotaxin 96.667 14 yes
tarc 96.667 14 yes
Sputum Non-Smoker edn 100 16 yes
Fibronectin 6.25 0 No
il-17 0 0 No
il8 100 16 yes
edn 100 16 yes
pge2 100 16 yes
saa 0 0 No
spd 34.375 3 No
tgf_b1 0 0 No
Smoker edn 96.667 14 yes
Fibronectin 15.625 2 No
il-17 0 0 No
il-8 62.5 8 yes
edn 87.5 13 yes
pge2 96.875 15 yes
saa 6.25 1 No
spd 70 8 yes
tgfb1 0 0 No
Only counted subjects who had concentration values > lloq and < uloq on both Day 1 and Day 2
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a challenge as this paper shows that many, relatively easily obtained markers that 
have previously been suggested to be associated with chronic airway inflammation 
fall short on these basic requirements for a useful biomarker. 
conclusion
spd proved to be a biomarker that fulfilled the criteria for reproducibility in both 
study groups. Furthermore, we found that chronic smokers compared to non-smok-
ers had higher concentrations of il-8 in induced sputum and spd in serum and 
lower concentrations of saa. 
abbreviations 
cv  Coefficient of Variation 
copd Chronic Obstructive  
Pulmonary Disease
edn Eosinophil derived  
neurotoxin
dtt Dithiothreitol
elisa Enzyme-linked  
immunosorbent essay
f  Female
fev1 Forced Expiratory Volume  
in 1 second
fvc Forced Vital Capacity
il-8 Interleukin 8
is  Induced sputum
la  Limits of agreement
ltb-4 Leukotriene B-4
m  Male
edn Monocyte chemotactic protein-1
pef Peak Expiratory Flow
pge2 Prostaglandin E2
rpm Round per minute
rl  Ratio Limit
rr  Reliability Ratio
saa Serum amyloid A
sec Second
sd  Standard deviation
spd Pulmonary Surfactant 
Associated Protein D
tarc Thymus and activation regulated 
chemokine
tgfb1 Transforming growth factor beta 1
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Table 2 Baseline demographics and clinical characteristics 
Non-smokers Chronic smokers
Number of subjects 16 16
Age (years) 41 (30-49) 41 (32-52)
Gender (m/f) 8m/8f 8m/8f
Height (meters) 1.75 (1.56-1.93) 1.73 (1.58-1.85)
Weight (kg) 77.5 (51.8-110.2) 73.1 (46.5-100.5)
bmi (kg/m2) 25.1 (21.1-29.5) 24.3 (18.6-30.0)
fev1 (L) 3.66 (2.75-5.16) 3.55 (2.38-4.64)
fev1 (% predicted) 102.9 (78-119.6) 102.7 (82.1-121.1)
fvc (L) 4.78 (3.21-6.42) 4.46 (3.15–6.38)
fvc (% predicted) 105.1 (82-131) 111.7 (76-127)
fev1/fvc 0.78 (0.59-0.91) 0.79 (0.72-0.89)
pef (L/sec) 9.98 (7.01-13.07) 9.67 (5.08-13.50)
Values are presented as mean (range)
Table 3 Sputum cell differentials  
Non-smokers Chronic smokers
Sputum cell count: Day 1 Day 2 Intra-subject 
CV (%)**






































* Values are given as mean (sd); ** cv(%): coefficient of variation
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anti-inflammatory effects in animal models, it only showed modest bronchodilation 
of short duration after inhaled administration in humans and resulted in cns and 
gastrointestinal side effects [12;13].
Classically first in human trials with novel drugs are conducted in healthy vol-
unteers using single and multiple ascending dose (sad/mad) designs with a focus 
on pharmacokinetics, safety and tolerability. This phase is then followed by sad/
mad studies in patients of the target populations in which also a first impression 
of the intended pharmacology is obtained. It would appear that such an approach 
with an inhaled, locally acting, compound is not necessarily informative. It is likely 
that a study design which combines the objectives mentioned above will be more in-
formative and cost-effective. We explored such an approach with the novel pde3/4 
inhibitor rpl554 which is developed for patients with asthma and copd. rpl554 is 
a trequinsin analogue with low human ic50 values for pde3 (400 pM) and pde4 
(1.5 μM) that has shown bronchodilation, bronchoprotective and anti-inflammatory 
properties in animal models of allergen-induced asthma and rhinitis [14].
The purpose of this first in human study was to identify a potentially effective 
dose and to assess in an early stage whether rpl554 possesses bronchodilative, bron-
choprotective and anti-inflammatory properties in patients with allergic asthma and 
rhinitis. To this purpose a step by step adaptive design was used. First, a safe dose of 
rpl554 was selected in healthy volunteers. Then, the potentially effective dose was 
selected in patients with allergic asthma. Finally, rpl554 effects were evaluated in 
more depth in both patients with allergic asthma and patients with allergic rhinitis.
methods
Design w In this study healthy volunteers and patients with allergic asthmatic 
and allergic rhinitis were administered a single dose of nebulized rpl554, Table 1. In 
two groups of 9 healthy volunteers, the safety and pharmacokinetics of 2 single doses 
of nebulized rpl554 (0.003 and 0.009 mg/kg) were sequentially evaluated. The 
highest dose was established as safe, and was used as the starting dose in two groups 
of 3 allergic asthmatics who received a single dose of nebulized rpl554 0.009 mg/kg 
or 0.018 mg/kg. Efficacy in this group was defined as an increase in pc20mch of at 
least 1.5 doubling dose post dose compared to baseline.
The highest established effective single dose of nebulized rpl554 (0.018 mg/kg) 
was studied in more depth in a subsequent group of 10 patients with mild allergic 
asthma in 10 patients with allergic rhinitis. In asthmatic patients efficacy was as-
sessed using change in fev1 and pc20mch, and in patients with allergic rhinitis, 
abstract
rpl554 is a phosphodiesterase-3 /4-inhibitor with bronchodilation, bronchopro-
tective and anti-inflammatory properties in animals. These characteristics were in-
vestigated for the first time in humans using an adaptive proof-of-concept-study. 
After dose escalation with rpl554 in healthy subjects, a potentially effective starting 
dose was chosen to investigate the protective effects against methacholine induced 
bronchoconstriction and to explore the effects on fev1 in asthmatics. The anti-in-
flammatory properties were assessed using a nasal allergen challenge in rhinitics. In 
asthmatic patients rpl554 resulted in substantial bronchodilation at doses between 
0.009 and 0.072 mg/kg with a mean increase at 1 hour of 520 mL (95%ci: 320; 720 
mL) at 0.018 mg/kg. Although increases in eosinophil count after the allergen chal-
lenge was lower in the prl554-treated group compared to placebo, 7.1% (p > 0.1, 
95%ci -2.2; 16.4%), anti-inflammatory properties of rpl554 could not statistically 
be established. This study demonstrates the bronchoprotective and bronchodilative 
properties of rpl554 in asthmatic patients using a swift and efficient clinical devel-
opment approach.
introduction
Maintenance therapy with inhaled corticosteroids (ics) supplemented with β2-
agonist are the cornerstone for the treatment of asthma [1]. Although treatment 
with ics results in a decrease of asthma related symptoms and improve lung func-
tion, even the highest doses of ics do not fully suppress the airway inflammation in 
all asthma patients [2;3] leaving many patients relatively uncontrolled [4]. Therefore, 
there is a continuous search for new effective therapeutic options for asthma 
treatment.
Inhibition of phosphodiesterase (pde) seems an attractive drug target particu-
larly when it would be possible to utilize the unique tissue distribution and resultant 
biological effects which characterized this family of enzymes [5]. Specifically, inhi-
bition of bronchial pde3 produces bronchodilation in patients with asthma [6;7], 
and pde4 inhibition would have anti-inflammatory properties and relax airway 
smooth muscle, which are all involved in the pathophysiology of chronic inflamma-
tory diseases like asthma [5]. It seems attractive to develop dual inhibitors as it has 
been suggested that dual inhibition results in synergetic effects [8;9]. This concept 
has been tested clinically before with a few dual pde3/4 inhibitors of which zar-
daverine is best known [10;11]. Although zardaverine showed bronchodilation and 
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[15] for first-in-man studies yielded a maximum starting dose of 0.01 mg/kg, a start-
ing dose of 0.003 mg/kg was selected, as this was assumed to be the initial pharma-
cological active dose. 
Drug administration took place by nasal inhalation of nebulized rpl554 through 
a facemask (Clement-Clarke adult oro-nasal face mask part no. L3605518), connect-
ed to a calibrated electronic nebulizer (Clement-Clarke International ac4000, uk; 
output: 7L/min at 1.00 bar) covering nose and mouth, while the subjects breathed 
normally through the nose. The nebulization time was 10 minutes for the lower dos-
ing groups (0.003 - 0.018 mg/kg rpl554), and 12 and 24 minutes respectively for the 
higher dosing groups (0.036 and 0.072 mg/kg rpl554).
Safety w Safety evaluation performed during the study to assess rpl554’s safety 
and tolerability consisted of the following safety measures: adverse events, physi-
cal examinations, blood biochemistry, haematology and coagulation (analysed at the 
Leiden University Medical Center), ecg, blood pressure and heart rate measure-
ments. Blood pressure and heart rate measurements were conducted by automat-
ed oscillometric equipment (bmk-1101K; Nihon Kohden, Japan, or Dash 4000; ge 
Healthcare, usa). Twelve-lead ecg recordings were made using Electrocardiograph 
Marquette 5000/5500 (usa) and in addition continuous ecg monitoring were per-
formed using an H12 recorder, (Mortara Instrument GmbH, Germany) in the lower 
dose groups.
Pharmacokinetics w To investigate the pharmacokinetics of rpl554, plas-
ma samples were drawn at regular intervals (at t = baseline and 15, 20, 30, 45 min and 
1, 2, 3, 4, 8, 24 hours) in 4 mL edta tubes, centrifuged within one hour for 10 m at 4 
C, 2000G, and stored for further analysis at -70-80C. rpl554 plasma concentrations 
were assayed using hplc methods by abl bv, Assen, The Netherlands. The pharma-
cokinetic analyses were performed by gbpk Consulting Ltd, uk.
Pharmacodynamics
Pulmonary function tests w Lung function was measured using the 
Vmax 20C pulmonary spirometer (SensorMedics, usa) at screening and during 
mch challenges. A portable spirometer zan 100 (Accuramed, Belgium) was used 
during study days. At approximately 15 and 5 minutes predose, baseline fev1 mea-
surements were performed and calculated as the average of the 2 highest of 3 fev1 
measurements (within 5%). Post-dosing measurements were performed in duplicate 
of which the highest, technically satisfactory fev1 was included into analysis.
efficacy was assessed by the inflammatory cell response following a nasal allergen 
challenge, sampled by a nasal brush. Finally, safety and bronchodilation effects of 
two higher doses rpl554 (0.036 and 0.072 mg/kg) versus placebo, were sequentially 
evaluated in two groups of 10 asthmatic patients. Details of the study characteristics 
are provided in Table 1. 
All subjects were assessed for eligibility during a screening session. In asthmatics 
who received 0.009 and 0.018 mg/kg rpl554, a methacholine challenge was per-
formed at 1 hour after study drug administration and in rhinitics, a nasal allergen 
challenge was performed at 40 minutes after inhalation.
Planned interim analysis after the completion of the first dosing groups (0.003, 
0.009 and 0.0018 mg/kg rpl554) were conducted to assess the initial safety and 
clinical effects of rpl554 and to establish the dose for the next stage. The Medical 
Ethics Committee of the Leiden University Medical Centre approved the study 
protocol. The study was performed according to Good Clinical Practice (gcp) and in 
accordance with the International Conference on Harmonisation (ich) guidelines.
Subjects w All volunteers were non-smoking males or ex-smokers (> 6 months 
abstinence and < 10 pack year) and did not suffer from any significant disease. The 
healthy volunteers used no medication and had a normal lung function; forced ex-
piratory volume in one second (fev1) and fvc > 90% of predicted and the fev1/fvc 
ratio > 80%. Asthmatic patients had mild to moderate persistent clinically stable al-
lergic asthma, require only treatment with short acting β2-agonists on an as needed 
basis. Also, they required a fev1 of > 70% of predicted, a positive provocation test 
with a fall in fev1 of > 20% (pc20mch) after < 4 mg/mL methacholine bromide and 
a positive skin prick test (spt > 3mm) for at least one allergen (grass or tree pollen, 
house dust mite, D. Farinae, cat, dog, or horse-dander, Aspergillus Fumigatus, A. 
Alternata or Artemisia Vulgaris). Furthermore, fev1 values had to be within 10% of 
each other on all study days and no history of respiratory tract infections at least 3 
weeks before enrollment or during the study. Rhinitic patients had a history of aller-
gic rhinitis for at least 6 months, a spt > 3 mm for house dust mite, pollen and or cat, 
and a Lebel composite symptom score of > 6 following intranasal allergen exposure. 
The asthma and rhinitis patients had not, except for inhaled short acting β2-agonists, 
used concomitant anti-asthma or anti-allergy medication for at least 2 weeks. 
Treatment w rpl554, a 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-
(Ncarbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-
4-one powder was diluted in a citrate-phosphate buffer of pH 3.2. The same buffer 
was used for placebo. Although the The Food and Drug Administration guidelines 
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study treatments using the same cumulative doses of allergen that had been shown 
to evoke an allergen-induced early upper airway response at screening (i.e. a Lebel 
score of at least 6).
Nasal brush w In rhinitics, nasal brushes were obtained from the same nos-
tril at the following times: baseline and 7 and 24 hours post-allergen, using a plastic 
nasal brush (Buccal Swab Brush, Biozym tc, the Netherlands). Immediately upon 
brushing, the brush was deposited in a 3 mL plastic tube containing 2 mL pbs (at 
room temperature). Subsequently, the cell suspension was centrifuged for 5 minutes 
at 390 G (1500 rpm) at room temperature, and mixed with of Trypan Blue and dried 
at room temperature. The differential counts were made by an experienced cytopa-
thologist and expressed as a percentage of a sample of at least 250 nucleated non-
squamous cells. 
eno w In rhinitics eno measurements were performed 10 min pre dose and 1.5 and 
7 hours post dose and executed according to current guidelines [22] using the mino 
(Aerocrine ab, Solna, Sweden). Subjects were sitting in upright position and wear-
ing a nose clip. They inhaled no-free air and subsequently exhaled for approximately 
10 seconds. The first technically acceptable measurement was used for analysis. The 
results were expressed in parts per billion (ppb).
Statistical analysis w One rhinitis patient completed the first period 
only. Therefore, his results were included in the safety analysis but excluded from the 
pharmacokinetic and pharmacodynamic analysis. As the first asthma patient in each 
of the highest dose group (0.036 and 0.072 mg/kg), were treated with rpl554 (open 
label), their pharmacodynamic data were not included into the analysis.
Pharmacokinetics w All pharmacokinetic parameters were calculated using 
non-compartmental analysis and using nca, WinNonLintm version 5.2, Model 
200. cmax and tmax were determined from visual inspection of the plasma con-
centration-time profile. The area under the plasma concentration-time curve from 
zero to the time of the last quantifiable plasma concentration, auc0-t, was calculated 
using the linear and log trapezoidal rule for the upswing and downturn in plasma 
concentration respectively. The rate constant of the slowest disposition phase (λz) 
was calculated by log-linear regression of the terminal portion of the concentration-
time profile. The plasma concentration-time curve from time zero to infinity (auc) 
was determined by using λz to extrapolate auc0-t to infinity. Total apparent drug 
clearance (cl/f) and the volume of distribution (Vz/F) were estimated by dividing 
methacholine bromide (mch) challenges w A methacholine 
challenge determines the degree of non-specific bronchial reactivity and was used 
as a measure for bronchoprotective effects in this study. mch challenges were per-
formed as previously described [16] and according to a standardized protocol [17], 
at screening and 60 minutes after dosing in the groups of allergic asthmatics who 
received 0.003, 0.009 and 0.018 mg/kg rpl554. In short, three technically satisfac-
tory fev1 measurements within 5% were performed pre and post diluent; the mean 
of the 2 highest fev1 values was included in analyses. The post diluent baseline 
had to be within 10% of the pre diluent baseline. Methacholine bromide ( Janssen 
Pharmaceutica, Belgium) was aerosolized by a DeVilbiss 646 jet nebulizer (output 
0.13 mL/min, Devilbiss Healthcare Inc., Somerset, usa) and inhaled during a 2 
minute tidal breathing with the nose clipped shut. Consecutive mbr doses (0.0625-
16 mg/mL) were inhaled at 5 minutes intervals and airway response was measured in 
duplicate following each dose (and expressed as percentage decline from post-dilu-
ent baseline fev1). The procedure was discontinued after a fall in fev1 of at least 20% 
from baseline occurred, or the highest permissible dose had been inhaled. Contrary 
to the routine procedure, rescue medication was not given at the end of the metha-
choline challenge at study days to enable estimation of the difference in fev1 recov-
ery following rpl554 versus placebo pretreatment.
Nasal allergen provocation test w The nasal challenge, which in-
vestigates the pathophysiological response in patients with allergic rhinitis after 
provocation with an allergen, was performed as previously described [18] in allergic 
rhinitics and was conducted according to a standardized method [19;20]. In short, 
the choice of the provocative allergen (hdm, grass pollen, or cat dander) was based 
on the size of the wheal response obtained in the spt in combination with the clini-
cal symptoms and seasonal time. Before the allergen challenge, the allergen’s dilu-
ent (phosphate-buffered saline containing human serum albumin 0.03% and ben-
zoalkonium-chloride 0.05%, alk Abelló) was sprayed into both nostrils (1 puff = 
0.125 mL/nostril), and subsequently the allergen (in up to 3 consecutive doses of 100, 
1,000 and 10,000 Biological Unites per mL) at 10 minutes intervals. The nasal re-
sponse was quantified pre-challenge, 10 minutes after each dose and at regular inter-
vals up to 24 hours afterwards, by the validated Lebel composite symptom scoring 
system [21]. The Lebel score describes and grades in allergen induced upper airway 
response, including: sneezing, rhinorrhoea, nasal blockage, nasal and ocular symp-
toms and pruritus, and consists of a linearly additive scale (0-3 points per symptom). 
Allergen dosing was discontinued if a Lebel score of 6 or more was reached. The 
nasal challenge was performed at screening and at 40 minutes after inhalation of the 
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kg increased the average heart rate compared to placebo with 3.1 beats per minute 
(bpm) (p = 0.45, 95%ci:-5.4; 11.5) and 8.9 bpm (p = 0.033, 95%ci: 0.8; 17.0) in asthmat-
ics, respectively. 
Pharmacokinetics w In healthy volunteers, inhalation of a single dose of 
rpl554 0.003 mg/kg resulted in plasma concentrations below the lower limit of 
quantification in all 6 subjects and after 0.009 mg/kg rpl554, plasma concentra-
tions could be measured in 4 out of 6 subjects for a short period after dosing, pre-
cluding detailed analysis. In asthmatics and rhinitics who received 0.018 mg/kg 
rpl554, plasma concentrations could be measured up to at least 8 hours, and at doses 
of 0.036 mg/kg and 0.072 mg/kg plasma concentrations of rpl554 were measured 
up to 24 hours. Figure 1 shows the rpl554 plasma concentrations time graph, and 
pharmacokinetic parameters are listed in Table 3.
pharmacodynamic
Bronchoprotection w In asthmatics, bronchoprotective action of inhaled 
rpl554 as measured by the pc20 methacholine challenge test (pc20mch) showed 
an average increase of 1.9 and 1.3 doubling doses for rpl554 0.009 mg/kg and 0.018 
mg/kg respectively, compared to baseline. Within each dose group, 2 out of 3 pa-
tients showed an increase in pc20mch of at least 1.5 doubling doses. In view of the 
fact that a dose of 0.018 mg/kg rpl554 was also well-tolerated and raised no safety 
concerns, this dose was further evaluated in a placebo-controlled manner in allergic 
asthmatics. In these patients, this dose led to an increase of approximately 1.46 dou-
bling doses change from baseline (p = 0.004, 95%ci: 0.63; 2.28) compared to placebo, 
Figure 2.
Bronchodilation w Across all dose groups in asthmatic patients, progres-
sive increase in fev1 was observed starting shortly after the inhalation of rpl554 
and reached a maximum after approximately 0.5-2 hour (Figure 3). In the group of 
asthmatics who received 0.018mg/kg rpl554, the maximum increase in fev1 was 
reached at approximately 60 minutes after dosing at which a planned methacholine 
challenge influenced the fev1 results from that point onwards. In the group of aller-
gic rhinitics, in which no methacholine challenge was performed, bronchodilation 
was observed for a more extended period. In asthmatics who received 0.036 mg/
kg and 0.072 mg/kg rpl554 and no concomitant methacholine challenge, broncho-
dilation was present up to 6 hours after dosing. The bronchodilation properties are 
provided in Figure 4 and Table 4.
the dose by auc, and product of λz and auc, respectively. The terminal half-life (t½) 
was derived from the equation ln(2)/λz. The exact dose nebulized by the subject was 
estimated by multiplying the mg/kg dose by the patient’s weight.
Pharmacodynamics w The pharmacodynamic end point were pc20mch 
and fev1 in the groups of asthmatics who were receiving 0.009 and 0.018 mg/kg 
rpl554, fev1 in the groups of asthmatics who were receiving 0.036 and 0.072 mg/
kg, and cellular infiltration in the group of rhinitics.
In all stages, descriptive statistics (mean, median, standard deviation (sd), mini-
mum and maximum) were used for numerical data, and counts and percentage of 
subjects in each category were used for qualitative data. fev1, nasal brush eosino-
phils and neutrophils, exhaled no and Lebel data were compared with a mixed 
model analysis of variance with fixed factors: treatment, period, time and treatment 
by time, random factors: subject, subject by treatment and subject by time and the 
average pre-value (average over baseline values before dosing and set at time=0) as 
covariate. eno data was log transformed before analysis. pc20mch doubling dose 
data were compared with a mixed model analysis of variance with fixed factors: 
treatment and period and random factor: subject. The contrast for rpl554 versus pla-
cebo was calculated and the data was presented as Least Square Means (lsms) with 
95% confidence intervals and the p-value of the contrast. All calculations were per-
formed using sas for windows V9.1.2 (sas Institute, Inc., Cary, nc, usa).
results
Demographics w A total of 65 subjects participated in the study, Table 2 and 
64 subjects completed the study. From the rhinitis patients, 7 out of 10 patients had 
concomitant clinically stable mild persistent asthma. All asthmatic subjects re-
mained stable throughout the study (fev1 within 10% of baseline value).
Safety and tolerance w Inhaled rpl554 was well tolerated in healthy 
volunteers, allergic asthmatics and allergic rhinitics. The most frequently reported 
adverse event included nasal congestion (n = 11), headache (n = 8), somnolence (n = 
7) and rhinorrhea (n = 4). These adverse events were reasonably equally distributed 
amongst rpl554 and placebo and amongst the different study populations. All ad-
verse events reported in the course of the study were mild in severity, short lasting 
and self-limiting. In addition, no clinically relevant changes were observed in ecg, 
physical examination and laboratory safety assessment. rpl554 0.036 and 0.072 mg/
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concentrations, a large apparent volume of distribution (exceeding 2500 L), a fast 
apparent clearance (exceeding 550 L/h) and a systemic terminal half-life of approxi-
mately 3 to 4 hours. Furthermore the mean cmax plasma concentrations were in the 
range of 2-3 ng/mL for the higher dose groups. In the lowest dose groups rpl554 
plasma concentration were even below the level of detection. These data suggest that 
systemic exposure after inhalation of rpl554 is low.
As expected the systemic exposure of nebulized rpl554 was low, but the expo-
sure in the lungs resulted in substantial bronchodilation and bronchoprotection in 
allergic asthmatics and rhinitics with concomitant asthma. With regard to bron-
choprotection, a dose of rpl554 of 0.018 mg/kg resulted in an increase of at least 1.5 
doubling doses in pc20mch allergic asthmatics, thereby reducing bronchial hyper-
responsiveness to inhaled methacholine. This increase in pc20mch seems superior 
to the bronchoprotective effects of the pde 3 inhibitor cilostozal (100 mg), which 
is less than one doubling dose in pc20mch after a single oral [24], and compares 
well to the protection obtained from 4 days b.i.d. inhaled salmeterol (50μg) and 
salbutamol (100μg) [25;26], demonstrating that a single dose of rpl554 shows potent 
bronchoprotection after inhalation.
Also the bronchodilation that we observed in allergic asthmatics was substantial; 
the maximum increase at approximately 1 hour after rpl554 nebulization (0.018 to 
0.072 mg/kg) ranged from 310 to 520 mL. Increases of this magnitude can be classi-
fied as significant and are similar to reported bronchodilation effects of salbutamol 
[27;28]. Although the study design slightly differed among the three higher dosing 
groups, i.e. cross over in the rpl554 0.018 mg/kg group and a parallel design in the 
0.036 and 0.073 mg/kg group, it might be that the maximum dose effect relation-
ship at one hour after nebulization had already been reached at the 0.018 mg/kg 
rpl554 dose. Any conclusions about the duration of the bronchodilation effects after 
nebulizing 0.018 mg/kg of rpl554 are hard to establish in allergic asthmatics since a 
methacholine test was performed after 1 hour after rpl554 inhalation in this group. 
However, in the higher dose groups the bronchodilation effect lasted for at least 6 
hours after inhalation of a single dose which compares favorably to the duration of 
inhaled salbutamol.
While the bronchoprotective and consistent bronchodilation properties in aller-
gic asthmatics were obvious, the anti-inflammatory effects after nasal allergen chal-
lenge and effects on eno as allergic rhinitics were less pronounced. We observed 
mitigated inflammatory response for rpl554 compared to placebo, but these effects 
did not reach statistical significance. Although Schmidt et al. suggested anti-in-
flammatory effects in allergic rhinitics (bm 2001) of pde4 inhibitors [29], our results 
might be hampered by the small sample size, the fact that the study did not take 
Anti-inflammatory effects w Although increase in eosinophils and 
neutrophils cell count induced by the allergen challenge at the 7 hour after dosing in 
allergic rhinitics was less under rpl554 (0.018mg/kg) compared to placebo (Figure 
5), this did not reach statistical significance; an estimated difference between pla-
cebo and rpl554 of 7.1% (p > 0.1, 95% ci: -2.2; 16.4%) and of 9.7% (p = 0.3, 95%ci: 
-10.5; 29.8%) was observed for eosinophils and neutrophils cell counts respectively. 
While eno values as measured in rhinitics appeared to be increased after rpl554 ex-
posure at 24 hrs after the nasal allergen challenge (Figure 5), the estimated difference 
of 6.3% (p = 0.40, 95%ci: -9.3; 24,6%) between rpl554 and placebo did not reach 
statistical significance. Nasal allergen challenge in rhinitics with a relevant allergen, 
evoked an early nasal response on the Lebel score in all patients in the presence of 
rp554 or placebo. No statistical significance could be reached between placebo and 
rpl554 at any point in time after the nasal allergen challenge (Figure 5); the estimat-
ed difference for the change from baseline between the treatments over the entire 
observation was 0.2 points (p = 0.4, 95%ci: -0.4; 0.9).
discussion
This study showed that inhalation of the dual pde3/4 inhibitor rpl554 is well toler-
ated up to a dose of 0.072 mg/kg. Mild and transient nasal congestion and rhinor-
rhea were observed, but these adverse events are likely to be related to the process of 
nasal inhalation of a nebulized substance and are not necessarily related to rpl554. 
The observed increase in heart rate during the administration of the highest rpl554 
could be considered as a pde-inhibitor-class-specific adverse event, as it possibly re-
flects a sympathetically mediated homeostatic reflex response occurring because of 
vascular smooth muscle relaxation, a well-known effect of pde3 inhibition. In gen-
eral, rpl554, administered by inhalation through the nose was well tolerated and did 
not raise any general or specific safety concerns. These findings contrast with previ-
ous studies that documented serious toxicities after administration of oral pde4 in-
hibitors. Abdominal complaints such as nausea, emesis, loose stools, loss of appetite 
and weight loss are some of the most reported side effects of roflumilast and cilomi-
last noted in clinical trials involving asthma and copd [5]. The serious (gastrointes-
tinal) side-effects occurring after multiple dosing with mk0359, a highly selective 
pde4 inhibitor, have resulted in cessation of its development [23]. The absence of 
gastro-intestinal side effect of rpl554 can be explained by the fact that the com-
pound was administered via the nasal route and the compound’s pharmacokinetic 
characteristics. The pharmacokinetics are characterized by rapid increase in plasma 
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Table 1 Summary of study characteristics
 






0.018 mg/kg 0.036 mg/kg
&
0.072 mg/kg
Population Healthy volunteers Allergic asthmatics Allergic asthmatics & 
Allergic rhinitics***
Allergic asthmatics
Design randomized randomized randomized
2 cohorts, parallel 2 cohorts, parallel cross over* parallel
placebo controlled placebo controlled placebo controlled**
double blind open label double blind double blind
Placebo/rpl554 
ratio per dose group
3/6 na na 3/7
* Cross over design including four week wash out periods; ** First patient was open label on rpl554 and 
therefore not used for comparison; *** Seven subjects with allergic rhinitis also had allergic asthma; na: not 
applicable
Table 2 Summary of subject characteristics
 






0.018 mg/kg 0.036 mg/kg
&
0.072 mg/kg
N. subjects 9 & 9 3 & 3 10 & 10 10 & 10
Population Healthy volunteers Allergic asthmatics Allergic asthmatics 
&Allergic rhinitics**
Allergic asthmatics
Age (years, range)* 24 (18-41) 25 (22-29) 29 (19-50) 26 (19-38)
bmi (kg/m2) * 23 (3) 23 (3) 25 (3) 25(4)
fev1 (l) * 4.81 (0.58) 4.28 (0.81) 4.33 (0.82) 4.12 (0.74)
fev1 predicted (%)* 105 (10) 87 (15) 94 (11) 92 (14)
pc20mch mg/ml* na 0.53 (0.87) 0.28 (0.46) &na 1.60 (1.46)
All value are obtained at screening; * Mean (sd); pc20mch was not measured in allergic rhinitics. Seven subjects 
out of ten with allergic rhinitis also had allergic asthma; na: not applicable
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place in an allergen free season, and especially for the eosinophilic cell count the rel-
atively large variability in the outcome measures. The findings may also be explained 
by the notice that anti-inflammatory effects may only occur after multiple dosing 
[29]. Thus, our data suggest anti-inflammatory effects of rpl554, but this property 
has to be investigated further.
The applied adaptive study design of the present study ascertained an efficient 
and swift early clinical evaluation of rpl554 which not only established its tolerabil-
ity and pharmacokinetics, but also its pharmacodynamic properties. The advantage 
of the applied adaptive approach is the selection of a safe and potentially effective 
dose in a small number of subjects first, before administering the compound to a 
bigger group of patients, leading to an increased likelihood of finding a pharmaco-
dynamic response in these groups. Although multiple doses of rpl554 were studied, 
the optimal dose selection remains uncertain. It appears that maximal bronchodila-
tion effects of rpl554 were already reached at dose of 0.018 mg/kg while only lim-
ited dose effect information was obtained in lower dose ranges, possibly leading to 
the need of an additional dose finding study. It should be noted that although an 
increase in pc20mch was established for rpl554, the bronchoprotective quality of 
rpl554 could be investigated further with e.g. an allergen challenge model, being 
a more robust method for the evaluation of anti-inflammatory properties and con-
troller therapy potential [30]. Furthermore, the effect on tolerance and safety with 
multiple dosing of rpl554 should be investigated, ideally before any further inves-
tigations on rpl554 controller therapy potentials are initiated, as the present study 
involve single dosing only.
In conclusion, single doses of nasally inhaled rpl554 over a dose range of 0.003 
to 0.072 mg/kg were shown to be safe in all subjects who enrolled in the study. 
The data show clinically relevant bronchodilative and bronchoprotective effects of 
rpl554 in allergic asthma. This study demonstrates a swift and efficient approach for 
the clinical development of this new pde3/4 inhibitor. Further studies with multiple 
dosing and/or allergen challenge studies are warranted.
Figure 1 rpl554 plasma concentrations up to two hours post dose, with sem error bars for the two highest 
doses
Figure 2 Allergic asthmatics: pc20mch change in doubling dose with sem, w p= 0.004 versus placebo
































l) 0.009 mg/kg rpl554 healthy volunteers
0.009 mg/kg rpl554 allergic asthmatics
0.018 mg/kg rpl554 allergic asthmatics
0.018 mg/kg rpl554 allergic rhinitics
0.036 mg/kg rpl555 allergic asthmatics
0.072 mg/kg rpl555 allergic asthmatics
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n 6 6 3 13 10 7 7
tmax (hours) nq nq 0.17 0.17 0.17 0.20 0.32
cmax (ng/ml) nq nq 0.96 2.21 1.8 4.3 4.2
vz/f (cv) (l) nq nq 1688 (10%) 3107 (39%) 2747 (38%) 2888 (29%) 3492 (45%)
cl/f (cv) (l/h) nq nq 553 (15%) 597 (41%) 626 (42%) 470 (23%) 586 (36%)
aucinf (cv)(ng.h/ml) 1.16 (16%) 2.79 (35%) 2.74 (32%) 6.3 (21%) 10.8 (21%)
t ½ (cv) (hours) nq nq 2.1 (7.0%) 3.9 (36%) 3.29 (45%) 4.2 (13%) 4.1 (17%)
All values are mean values except for tmax for which median values are used; nq: not quantifiable; cv: coefficient 
of variation expressed in percentage.
Table 4 Bronchodilation properties of rpl554 
dose rpl554 0.018 mg/kg 0.018 mg/kg 0.036 mg/kg 0.072 mg/kg
Population Asthmatics Rhinitics** Asthmatics Asthmatics
fev1 (ml)*
rpl554 vs placebo  
at 1 hour post dose
520 ml
p < 0.0001,








95%CI: 60;  
560 ml
fev1 (ml)*
rpl554 vs placebo 
















95%CI: -50;  
360 ml
* Measured by Least Square Means ; ** Seven out of ten rhinitic patients had concomitant asthma;  
na: Not applicable
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Figure 4 Box whisker plot for the maximum change in fev1 from baseline (with median, inter quartile 
range, 5th and 95th percentile range) for different doses of rpl554 in allergic asthmatics. The 0.018 mg/kg 
rpl554 dosing group includes the 7 patients with allergic rhinitis who were also suffering from allergic asthma 
Figure 5 Inflammatory markers in allergic rhinitics, change from baseline as lsms with sems error bars
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Figure 3 fev1 (l) change from baseline as lsms with sems error bars
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chronic inflammatory diseases like asthma [4]. It has been suggested that pde3 and 
pde4 together act synergetic as each pathway affects the function of different cell 
types [5]. The dual pde3/4 inhibitors studied so far in humans are all associated with 
unfavorable side effects [6;7], such as central nervous system (cns) and gastrointes-
tinal complaints. 
To prevent these systemic side effects, rpl554, a novel dual pde3/4 inhibitor to be 
administered by inhalation, was developed for the treatment of asthma. As rpl554 
is administered directly into the airways, systemic exposure will to be low. rpl554 
is a trequinsin analogue with human ic50 values for pde3 and pde4 of 400 pM and 
1.5 μM respectively [8]. It has shown bronchodilation, bronchoprotective and anti-
inflammatory properties in animal models of allergen-induced asthma and rhinitis. 
Safety and bronchodilation characteristics were investigated for the first time in hu-
mans at the Centre for Human Drug Research in Leiden, the Netherlands; rpl554 
significantly produced bronchodilation at doses between 0.009 and 0.072 mg/kg 
with a mean maximal increase of 520 mL (95%ci: 320; 720 mL) in patients with mild 
to moderate asthma without cns and gastrointestinal side effects. During metha-
choline challenge tests, rpl554 led to an increase of approximately 1.46 doubling 
doses change from baseline (95%ci: 0.63; 2.28) compared to placebo demonstrating 
both bronchoprotective and bronchodilative properties of rpl554 in asthmatic pa-
tients. The combination of both bronchoprotective and bronchodilatory properties 
with the absence of cns and gastrointestinal side effects is promising for the further 
development of rpl554 for the treatment of allergic asthma. 
Asthma therapy often starts at a young age and is given over many years. As con-
tinuous use of medication can be associated with a decline in drug effectiveness, lon-
ger term effectiveness of rpl554 might be a concern. Therefore, the next step in the 
development of rpl554 as a potential novel treatment for allergic asthma is to in-
vestigate rpl554’s effectiveness after repeated administrations. In the present study, 
lung function is assessed after repeated daily dosing of rpl554 for 6 consecutive days, 
to investigate the sustainability of effect on fev1.
methods 
Design w The study consisted of a single arm active treatment, assessing the 
bronchodilator effects of 6 repeated inhaled daily doses of rpl554 (0.018 mg/kg) 
in 13 patients with allergic asthma in a single blind manner. Visits to the clinic oc-
curred at screening and at study days: Day -1 for baseline assessments and place-
bo administration, Day 1 to 6 for daily dosing of rpl554, and Day 7 for follow-up. 
abstract
Aim To investigate the safety, tolerability and effect of repeated daily doses of 
nebulized rpl554, a dual phosphodiesterase 3/4 inhibitor.
Method Thirteen clinically stable allergic asthmatics received placebo on the 
first day and subsequently nebulized rpl554 (0.018 mg/kg) for 6 consecutive days in 
a single blind manner. fev1 was measured during 6 hours after administration.
Result The mean estimated half-life of rpl554 in plasma was 7.4 hours. The me-
dian (range) value for accumulation on Day 6, based on aucτ ratio, was 1.17 (0.64 to 
2.28). Repeated dosing of nebulized rpl554 caused consistent bronchodilation on 
all 6 consecutive days. An increase in mean fev1 after rpl554 compared to placebo 
was 312.9, 300.5 and 275.4 mL on day 1, 3 and 6 respectively. The maximum increase 
in fev1 compared to placebo on day 1, 3 and 6 was 555, 505 and 485 mL, respectively. 
Only a small decline in fev1 of 38 mL (95%ci:-95.9; 20.9 mL) or 12% on day 6 com-
pared to day 1 and corrected for placebo was observed. The most frequent report-
ed adverse events were headache, irritation of the larynx and dryness of the throat. 
Heart rate increased with 5 bpm (95%ci: 3.6; 7.4) and diastolic blood pressure de-
creased with 3.3 mmHg (95%ci: -5.6; -1.1) on day 6 compared to placebo. 
Conclusion Repeated daily doses of nebulized rpl554 0.018 mg/kg in allergic 
asthmatics for 6 days showed consistent bronchodilator effects and was generally 
well tolerated. 
introduction
Treatment of asthma currently consists of two distinct categories of drugs: reliev-
ers like β2 agonists which are used on an as needed basis and act quickly to reverse 
bronchoconstriction and relieve symptoms, and controllers like glucocorticosteriods 
which are taken daily on a long term basis to keep the asthma under clinical control 
[1]. A potentially new group of anti-asthmatics drugs is the selective phosphodies-
terase (pde) 3/4 inhibitor which may have both bronchodilation effects and anti-in-
flammatory properties. pde3 inhibition produces bronchodilation [2;3], while pde4 
inhibition results in anti-inflammatory and disease modifying features as pde4 
regulates the function of several immune, inflammatory (neutrophils, eosinophils) 
and structural cells (e.g. airway smooth muscle) involved in the pathophysiology of 
chapter 7 – repeated dosing of rpl554 elicits sustained bronchodilator effects in allergic asthmatics 
∂ 115 ∂
section i1 – clinical studies with a new anti-asthmatic drug 
∂ 114 ∂
Pharmacokinetics w Plasma samples, to assess the concentration of rpl554, 
were drawn at regular intervals (t = 0, 0.25, 0.5, 1, 2 and 4 hours post dose on days 1 
up and till 6 and in addition at 6 hours on days 1, 3 and 6) in 4 mL edta tubes. The 
samples were centrifuged within one hour for 10 minutes at 4° C, 2000G, and stored 
until analysis at -70 °C. rpl554 plasma concentrations were determined with a vali-
dated hplc method by abl bv, Assen, The Netherlands.
Pharmacodynamics Pulmonary function tests w Lung function 
tests were performed with the Vmax 20C pulmonary spirometer (SensorMedics, 
usa) at screening. A portable spirometer zan 100 (Accuramed, Belgium) was used 
during study days. At approximately 15 and 5 minutes predose, baseline fev1 mea-
surements were performed and calculated as the average of the 2 highest out of 3 
fev1 measurements (within 5%). Post-dosing measurements were performed in du-
plicate at regular intervals (t = 0, 0.25, 0.5, 1, 1.5 and 2 hours post dose on study days 
1 up and till 6, and in addition on 2.5, 3, 3.5, 4, 4.5, 5, 5.5 and 6 hours on study days 1, 3 
and 6) of which the highest, technically satisfactory fev1 was included into analysis.
Methacholine Bromide challenges (mch) w Methacholine chal-
lenge performed at screening was used to determine the degree of non-specific 
bronchial reactivity. mch challenges were performed by tidal breathing method 
according to a standardized protocol [9;10]. In short, three technically satisfactory 
fev1 measurements within 5% were performed pre and post diluent; the mean of 
the 2 highest fev1 values was included in analyses. The post diluent baseline had 
to remain within 10% of the pre diluent baseline, or otherwise the subject would 
be excluded from the study. Methacholine bromide (mbr) ( Janssen Pharmaceutica, 
Belgium) was aerosolized by a DeVilbiss 646 jet nebuliser (output 0.13 mL/min-
utes, Devilbiss Healthcare, inc, Somerset, usa) and inhaled during 2 minutes tidal 
breathing with the nose clipped. Consecutive mbr doses (0.0625-16 mg/mL) were 
inhaled at 5 minutes intervals and airway response was measured in duplicate fol-
lowing each dose (and expressed as percentage decline from post-diluent baseline 
fev1). The procedure was discontinued after a fall in fev1 of at least 20% from base-
line occurred or the highest permissible dose had been inhaled.
Pharmacokinetic analysis w The pharmacokinetic analyses were based 
on a non-compartmental analysis and calculated in Phoenix WinNonLin 6.2. 
cmax and tmax were determined from visual inspection of the plasma concen-
tration-time profile. The area under the plasma concentration-time curve from zero 
to the time of the last quantifiable plasma concentration, auc0-t, was calculated 
using the linear and log trapezoidal rule. aucτ was defined as the auc from zero 
Spirometry with frequent fev1 measurements was performed on all study days, 
Figure 1. Subjects only proceeded to the next dosing day, when stable and no clini-
cally relevant adverse events had occurred. The study protocol was approved by the 
medical ethical committee Stichting Beoordeling Ethiek Biomedisch Onderzoek 
(bebo) in Assen, the Netherlands and conducted according to the principles of the 
“Declaration of Helsinki” and the pertaining Dutch law.
Subjects w Thirteen male subjects with mild to moderate persistent clinically 
stable allergic asthma participated in the study. All subjects were non-smoking or 
ex-smokers (> 6 months abstinence and < 10 pack years) and did not suffer from any 
other significant disease. Patients only used short acting β2-agonists pro re nata, had 
a fev1 of > 70% of predicted, a positive provocation test to inhaled Methacholine 
with a fall in fev1 of > 20% (pc20mch) after < 8 mg/mL, methacholine, and a posi-
tive skin prick test (spt > 3mm) for at least one allergen (grass or tree pollen, house 
dust mite, D. Farinae, cat, dog, or horse-dander, Aspergillus Fumigatus, A. Alternata 
or Artemisia Vulgaris). fev1 values at screening and day -1 were within 10% of each 
other. Patients had a documented reversibility in lung function of > 12% or 0.2 L 
increase in fev1 after 200 μg salbutamol and had no history of respiratory tract in-
fections at least 3 weeks before enrollment and during the study. They had not, ex-
cept for occasional inhaled short acting β2-agonists which was not allowed within 
8 hours before start of the study days, used concomitant anti-asthma or anti-allergy 
medication in the weeks prior to the screening.
Treatment w rpl554 is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-
(Ncarbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-
4-one powder and was diluted in a citrate-phosphate buffer of pH 3.2. The same buf-
fer was used for placebo. Drug administration took place by oral inhalation of nebu-
lized rpl554 (0.018 mg/kg and based on an average weight of 65-70 kg) through 
a mouth piece connected to a calibrated electronic nebuliser (Clement-Clarke 
International ac4000, uk) while the nose was clipped. The drug solution was nebu-
lized from a 0.6 mg/mL solution at a rate of 0.2 mL/minute during 10 minutes.
Safety w Safety evaluation contained the recordings of adverse events, physi-
cal examinations, blood chemistry, haematology and coagulation (analysed at the 
Leiden University Medical Center), twelve lead ecg, blood pressure and heart rate 
measurements. Blood pressure and heart rate measurements were conducted daily 
by automated oscillometric equipment (bmk-1101K; Nihon Kohden, Japan, or Dash 
4000; ge Healthcare, usa). Daily Twelve-lead ecg recordings were made using 
Electrocardiograph Marquette 5000/5500 (usa). 
chapter 7 – repeated dosing of rpl554 elicits sustained bronchodilator effects in allergic asthmatics 
∂ 117 ∂
section i1 – clinical studies with a new anti-asthmatic drug 
∂ 116 ∂
pharmacodynamic analysis. The reversibility test, using inhalation of 200 μg salbuta-
mol, showed an average increase in fev1 of 0.49 L or 12.7%.
Safety and tolerability w The most common adverse event were head-
ache (n= 4), dizziness (n = 3) and larynx irritations (n=3). All events occurred as 
single events, were mild in intensity and transient. Table 2 provides an overview of 
the most important vital signs and ecg parameters. Heart rate increased around 5 
beats per minute and the diastolic blood pressure decreased with 3.3 mmHg on day 
6 compared to placebo (day -1). Furthermore, a decrease in the qt interval compared 
to placebo emerges, which disappears after applying Frederica’s correction method. 
In addition, there were no serious adverse events and no relevant changes observed 
in laboratory safety assessment and on the ecg parameters: rr-, pr-, qrs- and 
qt-intervals.
Pharmacokinetics w Results of rpl554 plasma concentrations are depicted 
in Figure 2 and the corresponding pharmacokinetic parameters are shown in Table 3.
Pharmacodynamic w Repeated dosing of nebulized rpl554 caused bron-
chodilation on all 6 consecutive days, Figure 3 and Figure 4. The increase in mean 
fev1 after rpl554 compared to placebo was 312.9, 300.5 and 275.4 mL on day 1, 3 and 
6 respectively. The maximum increase in fev1 compared to placebo on day 1, 3 and 6 
was 555, 505 and 485 mL, respectively. The differences in the least square mean for the 
change in fev1 corrected for placebo, between day 3 and day 1 was -4% or -12.4 mL, 
(p = 0.66, 95%ci:-70.9; 46.0 mL) and between day 6 and day 1 was -12 % or -37.5 mL 
(p = 0.20, 95%ci:-95.9; 20.9 mL). The corresponding estimated difference for the 
maximum fev1, corrected for placebo, between day 3 and day 1 was -9.0% or -50.0 
mL (p = 0.11, 95%ci: -113; 12.9 mL) and between day 6 and day 1 was -12.6% or -70 
mL (p = 0.03; 95%ci:-133; -7.1 mL). On day 6, fev1 results were characterised by a 
small decline in lung function at around 3 hours after dosing which was apparent in 
10 of the 12 evaluated patients on day 6 and absent on other days of the study.
discussion
Previous studies with single doses of nebulized rpl554 showed strong bronchodila-
tion and possible bronchoprotective effects in asthmatic patients, without signifi-
cant side effects. These data are promising for the further development of rpl554 as a 
potential treatment of allergic asthma.
to 24 hours post dose on each dosing day. The rate constant of the slowest disposi-
tion phase (λz) was calculated by log-linear regression of the terminal portion of 
the concentration-time profile. The terminal half-life (t½) was derived from the 
equation ln(2)/ λz. Total apparent drug clearance (cl/f) and volume of distribution 
(Vz/F) were estimated by dividing the dose by aucτ, and product of λz and auc, re-
spectively. The observed accumulation ratio (Rac) was estimated as follows: I) from 
the observed ratio (aucτ/ auc0-24) where τ was 48 to 72 h (Day 3) and 120 to 144 h 
(Day 6), and ii) from the observed ratio (Cmin, day n/Cmin,d2) where n = Day 3 
and Day 6 respectively. The used Cmin reflects the pre-dose plasma concentration 
measured prior to dosing on the given day.
Pharmacodynamic analysis w To compare the fev1 measures for 6 
hours post dosing at day 1, day 3 and day 6, fev1 results normalized for each individ-
ual to fev1 at day -1 were analysed using a mixed model repeated measures analysis 
of variance with day, time, day by time as fixed factors and subject, subject by time 
and subject by day as random factors. The difference between two days (-1 and 1, -1 
and 3, -1 and 6, 1 and 3, 1 and 6, 3 and 6) were used as contrasts and expressed as esti-
mated least square mean difference in rpl554 effect, together with the correspond-
ing estimated percentage difference, the 95% confidence interval and the p-value. 
Power calculation w A priori, the sample size of the study, as calculated 
with nQuery Advisor V5.0 (Statistical Solutions, Ltd, Cork, Ireland), was based 
upon intra individual variability in fev1 obtained from previous studies with single 
doses of rpl554. Using a standard deviation of the differences of 180 mL, a decrease 
of 50% in treatment effect between day 1 and day 6 (corresponding to around 150 
mL decrease in the drug response over 6 hours) could have been detected with a 
power of 80% and a significance level of 5% and 14 subjects. After 8 subjects the sd of 
the differences between days was estimated. This estimate revealed an sd of 97 mL 
leading to a subsequent recalculated sample size of 12 patients which would be an 
adequate number to detect a difference in treatment effect of 87 mL.
results
Demographics w A total of 13 patients with mild to moderate persistent clini-
cally stable allergic asthma were recruited and received rpl554 of which 12 subjects 
completed the study, Table 1. One subject withdrew his consent on day 1. His results 
were included into safety and pharmacokinetic analysis but were excluded from the 
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mediated homeostatic reflex response to the observed tendency for a fall in blood 
pressure that occurs because of relaxation of vascular smooth muscle, a well-known 
effect of pde3 inhibition (smpc amrinone, milrone, olprinone and cilostazol). 
Furthermore, although the qt interval decreased as a result of heart rate increase, 
the qt interval as corrected with Fridericia’s method remained stable, suggesting 
that rpl554 did not affect cardiac repolarization. 
Although the design of the study provided the fundament to answer the primary 
objective on acute tolerance, the robustness of bronchodilation over longer period 
of time should be investigate in more extensive follow up studies, preferably with an 
active comparator. Given that duration of bronchodilation of a single dose of rpl554 
lasts for several hours, a short acting β agonist would have been a reasonable con-
trast. However, the use of placebo on day -1 provided sufficient information to judge 
rpl554 on its own merits. The present study did not make use of a methacholine 
challenge as a measurement for tolerances, as the main outcome of this study was re-
lated to bronchodilation and not to bronchoprotection. However, as decreased pro-
tection against bronchoconstrictor stimuli like methacholine or histamine is a well-
known effect of long term treatment with long acting β2 agonists [12;13], measuring 
bronchoprotection is something to consider in future studies with rpl554.
In conclusion, repeated daily doses of nebulised rpl554 0.018 mg/kg in allergic 
asthmatics for 6 days showed sustained bronchodilator effects during the study pe-
riod and was generally well tolerated. The data suggest that acute tolerance to the 
effect of rpl554 does not develop during 6 days of continuous drug administration. 
Whether longer term treatment with rpl554 results in a clinically significant de-
creased effect, needs to be determined in subsequent clinical trials.
As asthma is a chronic condition, continuous drug use is often required. Tolerance 
for asthma medication has been described before for short-acting β2 adrenoceptor 
agonists, however it has generally been considered as non-clinically significant [11]. 
For the further development of rpl554 as a potential anti-asthma medication which 
inhibits pde3/4, we investigated whether rpl554 did not lose its effectiveness, and 
studied especially the occurrence of acute tolerance, after repeated daily dosing. We 
report that six repeated daily doses of nebulized rpl554 (0.018 mg/kg) in allergic 
asthmatics was well tolerated and resulted in sustained bronchodilation.
Bronchodilation effects, expressed as mean and maximum increase in fev1 com-
pared to placebo, were sustained throughout the study. Nevertheless, a small de-
crease in fev1 on day 3 and 6 and compared to day 1 was detected during the study 
period but felt within the observed standard deviation of the differences. The de-
crease in maximum fev1 on day 6 compared to day 1 however was significant. We 
believe that during the time period of the study the decline in fev1 did not influence 
the beneficial effects of rpl554 and was certainly too small to underpin the presence 
of acute tolerance, as the maximum increase in fev1 of 485 mL on day six compared 
to placebo still matches up to the observed effects of salbutamol during the revers-
ibility test. 
It was observed that the fev1 results on day 6 were characterised by a decline in 
lung function at around 3 hours after dosing. This decline was apparent in 10 of the 
12 evaluated patients on day 6 and absent on other days of the study. However the 
observation was classified as spurious as no satisfactory explanation could be found; 
all procedures were identical during all study days, subjects had limited room to ma-
noeuvre on a smoking free ward and lung function tests were performed by a team 
of experienced lung function technicians who worked in shifts in a random schedule 
throughout the study.
There was a minimal though variable accumulation of rpl554 which is reflected 
in the median ratio and range of Rac estimated using both auct and Cmin. The 
inter-patient variability noted in Rac was greater following estimation by Cmin 
ratios compared with the auct ratios. This observation likely reflects the variability 
inherent in a point estimate such as Cmin compared with the auc parameter which 
represents pk behaviour over a period of time. The systemic exposure to rpl554, as 
reflected in low concentrations for cmax and auct , can be regarded as little, which 
might explain the relative mild side effect profile. Indeed, only a few adverse events 
like mild headache and dizziness were reported. The observed decrease in diastolic 
blood pressure, the increase in heart rate and the subsequent decrease in qt-interval 
along the course of the study could be considered as a pde-inhibitor-class-specific 
adverse event. The observed increase in heart rate possibly reflects a sympathetically 
 
Table 3 Pharmacokinetic parameters of rpl554
Day 1 Day 3 Day 6
n = 13 n = 12 n = 12
cmax (pg/ml) 2136 (1454) 2041 (1215) 2269 (1369)
cmin (pg/ml) na 12 (7) 15 (12)
t1/2 (h) nc nc 7.4 (3.0)
aucτ (pg/ml)* 2111 (44%) 2056 (56%) 2730 (36%)
vz/f* (L) nc nc 5117 (68%)
cl/f* (L/h) nc nc 498 (41) %
rac using Cmin** na 1.26 (0.24-2.96) 1.18 (0.16-6.42)
rac using auc** na 0.90 (0.44-2.48) 1.27 (0.64-2.28)
Values given as mean (sd); *Values given as geometric mean (cv%) ; ** Values given as median (range);  
aucτ : refers to post dose values, covering 0-24, 48-72 and 120-144 hours for day 1, 3 and 6 respectively.;  
cmin : refers to the pre dose concentration; vz: apparent volume of distribution; cl: clearance; f: biological 
availability; rac: accumulation ratio; nc: not calculated 
Figure 1 Overview of study design. mch: methacholine challenge. fev1 was measured at frequent intervals 
during the study days
Figure 2 rpl554 plasma concentrations with sd error bars
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screening day ‐1 day 1 day 2 day 3 day 4 day 5 day 6 follow up   
mch x
reversibility test  x
fev1 x x x x x x x x x
study medication  placebo rpl554 rpl554 rpl554 rpl554 rpl554 rpl554
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Table 1 Baseline Patient characteristics
Number of subjects 13
Age (years) 26 (19-52)
bmi (kg/m2) 23.0 (1.81)
fev1 (l) 3.99 (0.66)
fev1 pred. (%) 88 (8.5)
fev1/fvc (%) 73 (8.2)
pc20mch (mg/ml) 1.68 (1.7)
All numbers are expressed in means (sd) expect age is expressed as mean (range)




































































































































Contrast given as difference (95%CI) and p – value. lsm: least mean square
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Figure 3 fev1 time profile with sd error bars
Figure 4a&b fev1 time profile (with sd error bars) for placebo at day -1 and day 1 and for placebo  
at day -1 and day 6
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were seen in patients with high levels of serum periostin, a protein produced by 
bronchial epithelial cells. This suggests that lebrikizumab may be useful for a specific 
group of patients with allergic asthma [13]. The compound is now in phase 3 trails. 
Dupilumab inhibits both il-4 and il-13 signaling and shows promising results in 
early clinical studies [14].
Eotaxin-3 and tarc are both chemokines for which no specific compound has 
been designed so far.
The allergen challenge model provides useful information on the ability of po-
tential controller therapies to block the asthmatic response. The model also offers 
high negative predicting values for effectiveness. Indeed, many - but certainly not all 
- novel compounds with anti-inflammatory characteristics have been studied using 
the allergen challenge to assess the efficacy of the compound in allergic asthma with 
fev1 as the main outcome parameter [14]. Few novel compounds however, have 
used the allergen challenge focusing on a panel of th2 driven cytokines rather than 
individual th2 cytokines, resulting in a more comprehensive insight in the phar-
macodynamic effects of investigated compounds [17]. This is curious, since expec-
tations are that this approach will result in a more robust predictive assessment of 
anti-inflammatory asthma medication in the early phase clinical drug development. 
The study described in chapter 2 contributes to this approach by determining the 
reproducibility and reversal effects of fluticasone of a wide range of cytokines and 
chemokines after allergen challenge in allergic asthmatic patients. 
Chapter 3 presents the results from microarray analysis of sputum samples ob-
tained from the study described in chapter 2. Little is known about microarray as-
sessment of gene expression in induced sputum obtained after allergen challenge 
in allergic asthmatics. It was found that microarray technology yields reproducible 
levels of gene expression in induced sputum following inhaled allergen challenge. 
Moreover, a refined allergen induced gene signature was effectively reversed by fluti-
casone and individual signatures correlated with lung function and eosinophil mea-
surements. It appears that this approach has the potential to further elucidate the 
complex interactions occurring during an inflammatory condition.
Limitations to the allergen challenge w Asthma is a heteroge-
neous disorder consisting of several ill-defined endotypes. Nevertheless, adult asth-
matic patients are likely to fall within 5 clusters, [18-20], Table 2.
The allergen challenge model triggers a th2 pathway inflammation. Initially, 
mast cell fixed IgE leads to the immediate phase of the asthma attack. In the late 
phase, which is in essence an progressive inflammatory reaction, th2 play a promi-
nent role [21]. th2 inflammation however, is not a hallmark for all clusters of asthma 
This thesis consists of two parts; section 1 contains chapters on biomarker applicability;  
section 2 describes the early clinical development of a new anti-asthmatic drug.
section 1
biomarker development and evaluation
chapter 2 & 3 Inhalation of allergens has been effectively and safely applied 
as a tool to evaluate new drug treatments for asthma, including inhaled steroids, 
anti-leukotriene therapy, and biologics including anti-IgE and anti-tnf-α thera-
pies [1]. The main application of these models in early drug development has been 
to estimate treatment changes in pulmonary function assessed by fev1, bronchial 
hyper-responsiveness (bhr) assessed by methacholine challenge, and changes in 
inflammatory state as assessed by cell counts after inhaled allergens. 
Chapter 2 investigated an extension of the allergen challenge model with the ability 
to quantify changes of a broad range of specific th2 cytokines in post allergen chal-
lenge collected sputum. 
The value of this study for currently developed asthmat-
ic drugs w The research pipeline for asthma contains a number of potentially 
new anti-inflammatory compounds and therapies with a need for pd airway bio-
markers [2], Table 1. The study in chapter 2 describes the combined use of ultracen-
trifugation with multiplex quantification methods of sputum biomarkers following 
allergen challenge, reversed by fluticasone. This approach allows for non-invasive 
identification of pharmacodynamic targets for anti-asthma therapies. In the study, 
the most notable effects, in terms of reproducibility and the reversal effect of flutica-
sone, were observed for il-5, il-13, eotaxin-3 and tarc.
Interleukin 5 is a key inflammatory cell mediator in the pathogenesis of asthma as 
it promotes the proliferation, differentiation, recruitment and survival of eosinophils 
[15]. High eosinophil counts in sputum are associated with poor asthma control, can 
predict future exacerbations, and can help direct medication changes. These findings 
suggest that il-5 may be an attractive target in allergic asthma. Mepolizumab is a 
monoclonal antibody treatment directed against il-5, and Mepolizumab treatment 
has resulted in a decrease in asthma exacerbations in patients with severe eosino-
philic asthma [12]. Benralizumab, a monoclonal antibody that targets α chain of the 
il-5 receptor, has shown promising results in phase 2 trials [16].
Interleukin 4 and il-13 are functionally and structurally related. Both induce B 
cells to produce IgE. Lebrikizumab is an il-13 monoclonal antibody. Improvements 
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Although it was found that chronic smokers had higher concentrations of il-8 in 
induced sputum and Pulmonary Surfactant Associated Protein D (sp-d) in serum, 
only sp-d out of a set of markers fulfilled the predefined criteria for reproducibility. 
Assessment of the feasibility of blocking il-8 w Although this 
study was carried out in a group of healthy chronic smokers, smoking plays a promi-
nent role in the pathophysiology of copd, and is associated with ~80% of the cases. 
In smokers, the disease is characterized as an inflammation that involves increased 
numbers of cd8+ (cytotoxic) Tc lymphocytes. These cells, together with neutrophils 
and macrophages, release inflammatory mediators like il-8. [28;29]. Increased con-
centrations of il-8 have been found in sputum and broncho alveolar lavage (bal) of 
patients with copd. il-8, also known as neutrophil chemotactic factor or cxcl8, is 
regarded as a pro-inflammatory factor. It induces chemotaxis in target cells, primar-
ily neutrophils but also other granulocytes, causing them to migrate toward the site 
of infection. il-8 also induces phagocytosis once they have arrived. Activation of the 
il-8 receptor, cxcr1 and cxcr2, has similar effects. Despite the biological plausibil-
ity, several cxcr2 antagonists and il-8 specific antibodies have been largely ineffec-
tive in clinical studies in patients with copd. As an example, the cxcr2 antagonist 
sb-656933 reduces sputum neutrophils in patients with copd. Larger studies how-
ever, have shown no clinical benefit [30;31].
It is difficult to pinpoint the reason for these failures. However, as is the case for 
asthma, numerous mediators are involved in the pathophysiology of copd. It thus 
appears that blocking a single mediator is unlikely to provide a major clinical ben-
efit, unless it is found to be solely responsible for orchestrating a cascade of inflam-
mation. This also highlights that the pathophysiology of copd is poorly understood. 
Therefore, it is unclear which cells could be promising therapeutical targets. It thus 
remains crucial to increase understanding of the underlying inflammatory mecha-
nisms of copd, and to identify biomarkers of disease activity that predict the clini-
cal efficacy of anti-inflammatory treatments. In this respect, analysis of sputum and 
serum parameters as described in chapter 5 may be useful. 
Assessment of the feasibility of sp-d w The story is different for 
Surfactant Pulmonary Associated Protein D (sp-d) than for il-8. The molecule is 
produced predominantly in the lungs and has been is recognized as an important 
regulator of innate immune system, capable of binding pathogens and facilitating 
phagocytosis [32]. It has microbicidal effect on certain bacteria and fungi and pro-
motes the elimination of viruses [33-35]. The lower levels of sp-d found in broncho 
alveolar lavage fluids in smokers may thus be a cause of weakened lung immunity. 
limiting the generalizability of the allergen challenge model, Table 2. Other limi-
tations include the need of experienced and well trained staff and the difficulty of 
recruiting eligible subjects.
chapter 4 Several biomarkers sampling methods are often used within the 
same clinical trials, in the same individual on the same day and sometimes even re-
peatedly. Most of them are validated and have proven importance in drug develop-
ment studies. But what if the complementary use of research tools causes them to 
interact with each other? 
Two frequently used sampling methods in asthma drug development studies are 
sputum induction (si) with hypertonic saline and fractional exhaled nitric oxide 
(feno). Both methods assess the airway inflammation for the lower airways in re-
sponse to e.g. new anti-inflammatory therapies. In chapter 4 the effect of si on feno 
measurements was investigated in healthy chronic smoking and non-smoking sub-
jects. The conclusion is that hypertonic saline decreased feno levels in both groups. 
As a result of the observed interference of si with feno measurements, the latter 
should always be measured before the si. There are several explanations for this ob-
servation: repeated spirometry measures as part of the si are known to result in de-
creased feno level [22]; mucus accumulation resulting from the si procedure could 
inhibit no diffusion from bronchial epithelial cells [23]; and osmotic changes in 
bronchial epithelium evoked by inhalation of hypertonic saline could have an effect 
on the inducible isoform of no synthase (nos) [24]. 
The effect of si on feno concentrations was already known; it was studied in 
healthy volunteers [25], in children [26] and in asthmatics [22]. Data demonstrating 
this effect in a group of chronic smokers was scarce. Therefore this study confirms 
and extends previous observations. 
Besides the direct effect of si procedures, smoking itself also has an effect on 
baseline feno concentrations. Indeed, in our study the feno levels were generally 
lower compared to the non-smokers group. In a more recent study, Hillas and col-
leagues showed that feno levels were significantly lower in asthmatic smokers com-
pared to non-smokers [27]. It would be interesting to assess the observed interaction 
between si and feno in a group of asthmatic smokers in a future study.
chapter 5 One of the hallmarks for biomarkers is that they must be reliable 
and reproducible. Chapter 5 evaluates the reproducibility of soluble markers ob-
tained from sputum induction and serum in a group of chronic smokers and a group 
of non-smokers. Soluble markers in blood and sputum samples were obtained on 2 
separate visits and analyzed with elisa. The results were somewhat disappointing. 
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the feasibility of the mass spectrometry maldi-tof-tof as a tool for biomarker 
discovery in induced sputum and plasma.
What would the advantage of such technologies be? Although still in their in-
fancy compared with other methodologies, large scale protein discovery stud-
ies could result in protein fingerprints which potentially could stratify patients for 
the treatment of copd and may provide a tool to assess treatment response [39;40]. 
However it is unlikely that these findings can be used plausibly or reproducibly as 
markers for the activity of a new medicine unless they are properly validated and 
underpinned by a mechanistic understanding of the changes in these profiles. If this 
is not done the risk of statistically spurious findings is probably high.
Section 2 
 
Clinical studies in healthy volunteers, allergic rhinitis 
and allergic asthma; with use of biomarker
In the second part of this thesis, the focus was on allergic asthma and the biomarker 
assisted development of the new anti-asthmatic drug rpl554.
Asthma and chronic obstructive pulmonary disease (copd) are commonly treat-
ed with a combination of a bronchodilator and an anti-inflammatory drug, usually 
an anti-inflammatory glucocorticosteroid. A drug that combines clinically relevant 
symptom control with substantial anti-inflammatory activity in one molecule would 
therefore be very welcome.
Phosphodiesterases (pde’s) are a large family of 11 enzyme subtypes, modulat-
ing intracellular concentrations like camp. Increased levels of camp are related to 
airway smooth muscle relaxation and anti-inflammatory actions. pde3 inhibitors 
cause airway smooth muscle relaxation in vitro [41;42], bronchodilation in vivo [43], 
and increases in forced expiratory volume in 1 second (fev1) in patients with asthma 
[44]. pde4 inhibitors inhibit the function of a wide range of inflammatory cells in 
vitro and have pronounced anti-inflammatory effects in patients with inflammatory 
airway disease [45;46]. Experimental data suggest that combined inhibition of pde3 
and pde4 iso-enzymes may have synergistic effects [47]. rpl554 is a dual pde3 and 
pde4 inhibitor that has shown bronchodilator and anti-inflammatory effects in ani-
mals in vitro and in vivo [48].
chapter 6 describes an experiment in which the effects of nebulized rpl554 
were assessed in a series of adaptive proof of concept studies. Both its bronchodilator 
In addition, spd is able to suppress inflammatory responses caused by lipopolysac-
charide (lps) [36]. sp-d is one of the few lung specific proteins that can be measured 
in serum, bypassing sometimes difficult and inconvenient sampling methods like 
bal and sputum induction. Furthermore, copd and copd-exacerbations are associ-
ated with higher levels of serum sp-d, which due to some unknown mechanism is 
inversely correlated with balf sp-d [37]. 
In our study we found that levels of serum sp-d in chronic smokers are up to 
twice as high compared to the levels of non-smokers. In addition, spd proved to 
be the only marker of a set of biomarkers to be reproducible in both smokers and 
non-smokers. Moreover, it has been found that regular inhalation of salmeterol and 
fluticasone lowers serum sp-d levels in copd patients [38].
Taken together, sp-d has an important role in the innate immunity, can be easily 
assessed in serum, is specific for copd, levels change with severity and exacerbations, 
and last but not least it is sensitive to effective treatment. This does not necessary 
mean that a sp-d compound should be developed. However, it does seem that sp-d 
may be a potential candidate marker with characteristics of a validated biomarker 
for copd.
Large scale protein discovery studies w The search for multiple 
disease specific protein biomarkers is sometimes called “a fishing expedition”, an un-
complimentary term indicating that scientists have no idea what the catch will be. 
Chapter 5 describes the results of identification of a broad array of analytes in spu-
tum using elisa technology. However, newer analytical technologies like multiplex 
analysis and peptidomics have exponentially increased the surface of the net allow-
ing more fish to be caught. In fact these two technologies were also applied in the 
study, but not described in the manuscript.
In our study, Multiplexed analysis (Rules Based Medicine) was used to mea-
sure a total of 92 soluble markers in serum. The analysis showed increased levels 
of Marcophage Derived Chemokine (mdc), Carcino-Embryonic Antigen and 
Apolipoprotein H in smokers compared to non-smokers. All other biomarkers were 
not significantly different for the two study groups. Reproducibility was not assessed 
and therefore this analysis was not mentioned in the article. 
For proteomics analysis, mass spectrometry maldi-tof-tof was used to assess 
the feasibility for primary screening of yet to be discovered biomarkers. Once a 
peptide marker is identified and its sequence validated, the next step is to develop 
a standard elisa assay. The elisa can then be applied to the same clinical samples 
and deliver quantitative measures of the biomarker. In our study, proteomics 
analysis identified 147 proteins in the supernatant of induced sputum demonstrating 
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Anti-inflammatory effects of rpl554 in the studies presented in chapter 6 en 7 were 
difficult to establish. pc20mch increased with 1,5 doubling dose compared to place-
bo. On the other hand, methacholine challenge only has moderate correlation with 
eosinophilic airway inflammation [55]. Also, rpl554 did not shown a significant ef-
fect on eosinophil cell count in patients with allergic rhinitis after a nasal allergen 
challenge, (chapter 6). Furthermore, rpl554 at a dose of 0,018 mg/kg continued to 
induce sustained bronchodilation in a group of mild allergic asthmatic volunteers, 
but it did not improve fev1 values at baseline at each study day, (chapter 7).
In conclusion, the bronchodilator effects of rpl554 are promising. However, its 
anti-inflammatory effects in asthma based on the observations in our studies and 
based on the limited effects of pde4 inhibitors on mast cells in general, will need to 
be determined in further clinical studies. 
rpl 554 for copd w copd is another inflammatory disease but the nature of 
the inflammatory response is different from asthma. copd is characterized amongst 
other reactions, by activation of macrophages and cells recruitment of neutrophils in 
the lung. Lipopolysaccharide (lps) challenges mimic the airway neutorophilia and 
have been used to evaluate the efficacy of new therapeutic agents for the treatment 
of copd. The inhibiting effect of rpl554 (0,018 mg/kg) on lps-induced sputum 
neutrophils was demonstrated in a placebo-controlled crossover trial with 21 healthy 
men [7], showing reduction in absolute numbers of neutrophils after 6 hours. The 
effect was similar to that observed with roflumilast in the sputum of patients with 
copd [46].
In addition, an open-label, placebo controlled crossover trial, in 12 men with 
mild-to-moderate copd showed a bronchodilator effect of rpl554 (0,018 mg/kg) 
with a mean maximum fev1 increase of 17,2% [7]. These effect are comparable with 
peak effects reported in such patients with inhaled β2 agonists [56], and suggest po-
tential therapeutic use of rpl554 in copd.
Overall conclusion
This thesis describes attempts to identify novel pathophysiology based biomarkers 
for chronic airway disease by applying newer detection techniques. It appears that 
such an approach may be worthwhile to pursue. Further, it shows that application of 
biomarkers allows effective development of new therapies in chronic airway disease.
and anti-inflammatory properties were investigated for the first time in humans. 
This single dose study was split into three stages. Safety of rpl554 was assessed in 
healthy individuals (stage 1), and safety and efficacy was assessed in otherwise 
healthy subjects with allergic asthma or allergic rhinitis (stage 2 & 3).
This experiment showed that rpl554 was well tolerated and had mild adverse 
events that were equal to placebo. In allergic asthmatic patients rpl554 at 0,018 mg/
kg resulted in an increase in pc20Mch of around 1,5 doubling doses and substantial 
bronchodilation at doses between 0.009 and 0.072 mg/kg with a mean increase at 
1 hour of 520 mL in fev1. The latter effect is comparable to that of salbutamol, a 
widely used β-agonist. Increases in eosinophil count after the nasal allergen chal-
lenge were reduced by prl554- compared to placebo (7.1%) although this did not 
reach statistical significance.
chapter 7 In another study with rpl554, described in chapter 7, the reproduc-
ibility of the bronchodilator response to a daily dose of nebulized rpl554 at 0,018 
mg/kg for 6 consecutive days in a placebo controlled study in 12 healthy men with 
allergic asthma was examined. This study showed that rpl554 had a similar maxi-
mum mean increase on day 1 (555mL) day 3 (505 mL) and day 6 (485 mL), suggesting 
that acute tolerance to the effect of rpl554 did not develop.
rpl554’s further development for asthma w As explained in the 
introduction of this thesis, the underlying pathophysiology of asthma is often – but 
not always - th2 driven and a consequence of the contribution of numerous cells 
including the epithelium, dendritic cells, T lymphocytes, eosinophils, mast cells and 
airway smooth muscle. Many of these cells express pde4 and inhibition of this en-
zyme could suppress the function of these cells [49]. 
When a new pharmaceutical agent for asthma is studied, its ability to block the 
early and late phase asthmatic response and subsequent airway hyperresponsiveness 
is important evidence for effectiveness [1]. So far, a few pde4 inhibitors have been 
assessed for their effect on the acute allergen induced bronchoconstriction. An inhi-
bition of the late phase response of around 30% was observed for cdp840 and roflu-
milast after several days of treatment [50;51]. In addition, the effect of gsk256066, an 
inhaled pde4 inhibitor, was regarded as modest [52]. However, roflumilast showed a 
30–50% reduction in sputum eosinophil number indicating anti-inflammatory ac-
tivity in asthma. However, the effect of roflumilast on allergen induced airway hy-
perresponsiveness was limited; around 1 doubling dose of methacholine [53]. These 
effects of roflumilast are modest when compared to the effect of fluticason (chapter 
2), and consistent with the lack of demonstrable action of pde4 inhibition on mast 
cell [54]. 
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Table 1 Summary of potential new therapies for asthma.  
Ultra long acting β2-agonists Effective for copd, possible available in near future for asthma - 
especially when combined with ics [3;4]
Long acting muscarine-antagonist Effective for copd, possible available in near future for asthma - 
especially when combined with ics [5;6]
pde-Inhibitors Favorable early studies [7]
Bronchial thermoplasty Effective but has possible immediate complications associated with the 
tnf-α Risk of side effects [9]
il-9 Not effective [10]
il-17 Not effective [11]
il-5 Effective in asthmatic patients with high eosinophil levels [12] 
il-13 Effective in asthmatic patients with high periostin levels [13]
il-4 Promising early studies [14]
Table 2 Clusters of asthma 
Cluster 1 Early onset allergic asthma with Th2 signature: high levels of eosinophils, mast cells,  
ige and feno
Cluster 2 Adult onset non allergic asthma. Th2 signature with eosinophilia and high levels of il-4, 
il-5, il-13, but absence of allergic disease
Cluster 3 Exercise induced asthma. Mast cells play an important role
Cluster 4 Prominent obesity and minimal Th2 response
Cluster 5 Sputum neutrophilia with Th17 response
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dat sputum inductie een verlaging geeft van de concentratie uitgeademde stikstof-
monoxide. Er zijn meerdere verklaringen mogelijk voor deze interactie. Allereerst is 
bekend dat meerdere opeenvolgende spirometrie metingen, die uitgevoerd worden 
bij sputum inductie, de stikstofmonoxide concentraties in uitgeademde lucht ver-
lagen. Daarnaast zou het ophopen van slijm in de longen, als gevolg van de sputum 
inductie procedure, de diffusie van stikstofmonoxide beperken. Verder is bekend dat 
de hypertoon zoutoplossing een osmotische verandering teweeg kan brengen waar-
door mogelijk de productie van stikstofmonoxide afneemt. Om deze interactie te 
vermijden verdient het aanbeveling om het bepalen van de stikstofmonoxide con-
centratie uit te voeren voorafgaand aan de sputum inductie.
Belangrijkste kenmerken van een biomarker zijn betrouwbaarheid en reprodu-
ceerbaarheid. Dat wil zeggen dat als het onderzoek onder dezelfde omstandigheden 
meerdere malen wordt uitgevoerd, de waarde van de biomarkers steeds hetzelfde 
blijft. Op basis van dezelfde studie als beschreven in hoofdstuk 4 werd de reprodu-
ceerbaarheid van de concentratie markers in geïnduceerd sputum en serum onder-
zocht in een groep chronische rokers en een groep niet-rokers. De concentraties van 
de markers werden bepaald met een elisa techniek. De resultaten van het onder-
zoek staan beschreven in hoofdstuk 5. Hoewel hogere concentraties in chronische 
rokers werden gevonden van il-8 in sputum en Surfactant Pulmonary Associated 
Protein D (sp-d) in serum, bleek dat uit een set van markers alleen sp-d voldeed aan 
de vooraf bepaalde criteria voor reproduceerbaarheid.
Sectie 2 
 
Klinische studies in gezonde vrijwilligers, patiënten met 
allergisch astma en rhinitis, met gebruik van biomarkers
hoofdstukken 6 & 7 In het tweede deel van dit proefschrift ligt de nadruk 
op allergisch astma en de klinische ontwikkeling van een nieuw anti-astma genees-
middel (rpl554) waarbij gebruikt wordt gemaakt van biomarkers. Astma en chro-
nisch obstructief longlijden (copd) worden veelal behandeld met een combinatie 
van luchtwegverwijders en ontstekingsremmende geneesmiddelen. Een geneesmid-
del dat tegelijkertijd luchtwegverwijding kan geven en ontstekingsremmend is, zou 
dus een aanvulling zijn op de bestaande behandelmogelijkheden. Fosfodiesterasen 
(pde’s) is een groep enzymen die wordt onderverdeeld in 11 subgroepen. Het ge-
meenschappelijk kenmerk van deze enzymen is dat ze concentratie camp in de cel 
verhogen door het remmen van de afbraak. Hogere concentraties camp leiden tot 
Dit proefschrift bestaat uit twee delen. Sectie 1 beschrijft de ontwikkeling van biomarkers 
voor chronische aandoeningen van de luchtwegen. Sectie 2 beschrijft de toepassing van 
biomarkers bij de ontwikkeling van mogelijk nieuwe geneesmiddelen tegen astma. 
 
 
Sectie 1  
 
de ontwikkeling van biomarkers in astma en copd
 
hoofdstukken 2 & 3 Het uitlokken van een astma aanval bij proefpersonen 
door het geven van een allergeen (bijvoorbeeld graspollen) is een effectieve en veilige 
onderzoeksmethode om de werking van nieuwe middelen tegen astma te onderzoe-
ken. Tijdens deze methode wordt veelal gekeken naar de effecten op de longfunctie, 
de gevoeligheid van de longen voor prikkelende stoffen en worden de ontstekings-
cellen in het sputum geanalyseerd. In hoofdstuk 2 werd dit model verder uitgewerkt 
en werd onderzocht of het bepalen van een grote groep ontstekingseiwitten ook ge-
bruikt kan worden als uitkomstmaat. De studie toonde aan dat het aantal door th2-
cellen geproduceerde eiwitten toeneemt na het ondergaan van een uitgelokte astma 
aanval, en ook dat deze toena me in veel gevallen reproduceerbaar is. Behandeling 
met fluticason heeft een duidelijk verminderend effect op deze toename van eiwit 
concentratie. Deze resultaten kunnen goed gebruikt worden om de effecten van een 
nieuw te onderzoeken geneesmiddel tegen astma in kaart te brengen. Hoofdstuk 3 
beschrijft de rna analyse op basis van dezelfde sputum monsters die in hoofdstuk 2 
zijn beschreven. Er is nog maar weinig bekend van een dergelijke analyse in sputum 
afkomstig van patiënten met een uitgelokte astma aanval. Gevonden werd dat ook 
het rna toeneemt na een astma aanval en dat deze resultaten reproduceerbaar zijn. 
 
hoofdstukken 4 & 5 Vaak worden in een klinisch onderzoek meerdere 
methoden gebruikt voor het verkrijgen van lichaamsmateriaal. De meeste van deze 
technieken zijn betrouwbaar en hebben hun waarde bewezen voor het gebruik in 
geneesmiddelen studies. Echter, gelijktijdig gebruik van twee of meerdere onder-
zoekstechnieken kan de uitkomst van de afzonderlijke technieken beïnvloeden. 
Twee methoden die frequent worden toegepast bij onderzoek naar nieuwe genees-
middelen voor astma zijn sputum inductie met hypertoon zout en het bepalen van 
concentratie stikstofmonoxide in uitgeademde lucht. Met beide methoden kan de 
mate van ontsteking in de longen worden bepaald. In hoofdstuk 4 wordt het effect 
van sputum inductie op de concentratie uitgeademde stikstofmonoxide bepaald bij 
een groep gezonde rokende en niet rokende manen en vrouwen. Er werd vastgesteld 
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samenvatting Dit proefschrift beschrijft het onderzoek naar nieuwe pa-
thofysiologisch gebaseerde biomarkers voor chronische luchtweg aandoeningen 
met behulp van nieuwe detectie technieken. Een dergelijke aanpak lijkt geslaagd. 
Verder laat het proefschrift het gebruik van biomarkers zien bij de effectieve ont-
wikkeling van nieuwe therapieën voor chronische luchtweg aandoeningen. 
verslapping van de gladde spieren in de long en tot ontstekingsremming. Binnen 
de groep pde-remmers zorgen pde3 remmers voor een verhoging van camp, wat 
leidt tot verwijding van luchtwegen waardoor het uitgeblazen volume in de eerste 
seconde van de longtest (fev1) bij patiënten met astma toeneemt. Remmers van 
het iso-enzym pde4 zorgen voor verminderde werking van een groot aantal ontste-
kingscellen en hebben een duidelijk ontstekingsremmend effect in patiënten met 
copd. Experimenteel onderzoek heeft aangetoond dat een combinatie van pde3 en 
pde4 remming leidt tot synergie; het effect op de luchtwegen is groter dan de som 
van beide afzonderlijke effecten. rpl554 is een middel dat zowel pde3 als pde4 remt.
In hoofdstuk 6 wordt beschreven hoe de verdraagbaarheid en effectiviteit van 
rpl554 over een brede reeks (0,03 tot 0,072 mg/kg) doseringen wordt onderzocht in 
een geneesmiddelenstudie. Zowel de bronchusverwijdende als de ontstekingsrem-
mende effecten werden voor de eerste keer in mensen onderzocht. Het onderzoek 
werd opgedeeld in 3 deelonderzoeken, waarbij eerst opklimmende eenmalige do-
seringen van rpl554 werden gegeven aan gezonde vrijwilligers en patiënten met al-
lergisch astma (1e deel), waarna een vaste dosering werd onderzocht in een groep 
patiënten met allergisch astma en allergisch rhinitis (2e en 3e deel). 
De onderzoeksresultaten lieten zien dat rpl554 over het algemeen goed werd 
verdragen. De bijwerkingen waren mild en de frequentie was te vergelijken met die 
van de placebo groep. In patiënten met astma zorgde een dosis van 0,018 mg/kg 
rpl554 tijdens de pc20 methacholine test voor een toename van 1,5 verdubbelde 
dosis. Verder bleek dat doseringen tussen 0.009 en 0.072 mg/kg een aanhoudende 
luchtwegverwijding gaven met een gemiddelde toename in fev1 op 1 uur na doseren 
van 520 mL. Dit laatstgenoemde effect is vergelijkbaar met het effect van de veel 
gebruikte β-agonist salbutamol. In de groep patiënten met allergische rhinitis werd 
ook een aanzienlijk bronchusverwijdend effect gemeten en waren er aanwijzingen 
voor een anti-inflammatoir effect. Het laatstgenoemde effect bereikte geen statis-
tisch significantie, maar de observatie dat de toename in eosinofielen na een nasale 
allergeen challenge 7,1% lager was na rpl554 in vergelijking met placebo, suggereert 
dat rpl ook ontstekingsprojecten kan onderdrukken.
In een vervolgstudie, beschreven in hoofdstuk 7, werd onderzocht of de luchtweg-
verwijdende effecten ook aanhouden als patiënten met allergisch astma gedurende 
6 achtereenvolgende dagen rpl554 gebruiken. Met dit onderzoek, dat werd uitge-
voerd in 12 patiënten met astma, konden we laten zien dat rpl554 een aanhoudend 
luchtwegverwijdend effect gaf en dat het effect vergelijkbaar was met de effecten die 
optreden na een enkele dosering; een gemiddelde maximale toename in fev1 op dag 
1 van 555 mL, op dag 3 van 505 mL en op dag 6 van 485 mL. Het lijkt er dus op dat 
rpl554 geen acute tolerantie laat zien bij langduriger gebruik.
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